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1 
Introduction 
 
 
 
Cancer is a genetic disease caused by uncontrolled proliferation and the inappropriate 
survival of damaged cells. Cells have developed several safeguards to ensure that cell 
division, differentiation and death occur correctly and in a coordinated fashion, both 
during development and in the adult body. Many factors are involved in the 
regulation of genes that direct cellular proliferation and differentiation. Damage to 
these genes, which are referred to as tumour-suppressor genes and oncogenes, is 
selected for in tumorigenesis. Most tumour suppressor genes and oncogenes belong 
to the wide category of protein coding genes, however, recent evidence indicates that 
small non coding RNA molecules, called microRNAs (miRNAs), might also 
function as tumour suppressors and oncogenes (Esquela-Kerscher et al., 2006).  
 
1. MicroRNAs 
 
MicroRNAs  are single-stranded RNAs of 19–25 nucleotides in length that are 
generated from endogenous hairpin-shaped transcripts (Ambros, V. et al. 2003; 
Bartel, 2004; Cullen et al., 2004 ). miRNAs function as guide molecules in post-
transcriptional gene silencing by base pairing with target mRNAs, which leads to 
mRNA cleavage or translational repression. With more than 700 members per 
species in higher eukaryotes, miRNAs are one of the largest gene families, 
accounting for ~1% of the genome (Bartel, 2004). Recent studies have revealed that 
miRNAs have key roles in several regulatory pathways, including control of 
developmental timing, haematopoietic cell differentiation, apoptosis, cell 
proliferation and organ development. miRNAs and their targets seem to form 
complex regulatory networks. For example, a single miRNA can bind to and regulate 
many different mRNA targets and, conversely, several different miRNAs can bind to 
and cooperatively control a single mRNA target (Lewis et al., 2003). Recent work by 
the Bartel and Burge laboratories predicted that over one third of all human genes are 
targeted by miRNAs (Lewis et al, 2005). Consequently, the unique combination of 
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miRNAs that are expressed in each cell type might affect or ‗dampen‘ the utilization 
of thousands of mRNAs (Bartel et al., 2004). Although the complexity of this 
regulatory circuitry is currently overwhelming, one of the first key steps towards 
dissecting the network would be to understand how miRNA genes themselves are 
regulated. 
 
1.1 The discovery of miRNAs  
 
MicroRNAs were identified for the first time in the 1993 from Victor Ambros, 
Rosalind Lee and Rhonda Feinbaum. They discovered that lin-4, a gene known to 
control the timing of C. elegans larval development, does not code for a protein but 
instead produces a pair of small RNAs (Lee et al., 1993).  One RNA is 
approximately 22 nt in length, and the other is approximately 61 nt; the longer one 
was predicted to fold into a stem loop proposed to be the precursor of the shorter one. 
The Ambros and Ruvkun labs then noticed that these lin-4 RNAs had antisense 
complementarity to multiple sites in the 3‘ UTR of the lin-14 (Lee et al., 1993; 
Wightman et al., 1993). This complementarity fell in a region of the 3‘ UTR 
previously proposed to mediate the repression of lin-14 by the lin-4 gene product 
(Wightman et al., 1991). The Ruvkun lab went on to demonstrate the importance of 
these complementary sites for regulation of lin-14 by lin-4, showing also that this 
regulation substantially reduces the amount of LIN-14 protein without noticeable 
change in levels of lin-14 mRNA. Together, these discoveries supported a model in 
which the lin-4 RNAs pair to the lin-14 3‘ UTR to specify translational repression of 
the lin-14 message as part of the regulatory pathway that triggers the transition from 
cell divisions of the first larval stage to those of the second (Fig. 1) (Lee et al., 1993; 
Wightman et al., 1993). 
For seven years after the discovery of the lin-4 RNA, the genomics of this type of 
tiny regulatory RNA appeared simple: there was no evidence for lin-4-like RNAs 
beyond nematodes and no sign of any similar noncoding RNAs within nematodes. 
This all changed upon the discovery that let-7, another gene in the C. elegans 
heterochronic pathway, encoded a second ≈ 22 nt regulatory RNA. The let-7 RNA 
acts to promote the transition from late-larval to adult cell fates in the same way that 
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the lin-4 RNA acts earlier in development to promote the progression from the first 
larval stage to the second (Reinhart et al., 2000; Slack et al., 2000). Similar to lin-4, 
let-7 performs its function by binding to the 3′ UTR of lin-41 and hbl-1 (lin-57), and 
inhibiting their translation (Reinhart et al., 2000; Lin et al., 2003; Abrante et al. , 
2003; Slack et al., 2000; Vella et al., 2004). The identification of let-7 not only 
provided another vivid example of developmental regulation by small RNAs, but 
also raised the possibility that such RNAs might be present in species other than 
nematodes. Both let-7 and lin-41 are evolutionarily conserved throughout metazoans, 
with homologues that were readily detected in molluscs, sea urchins, flies, mice and 
humans (Pasquinelli et al., 2000). This extensive conservation strongly indicated a 
more general role of small RNAs in developmental regulation, as supported by the 
recent characterization of miRNA functions in many metazoan organisms. 
 
 
 
 
Figure 1. The molecular hallmarks of lin-4, the founding member of the microRNA family. 
a) The precursor structure and mature microRNA (miRNA) sequence of lin-4. b) Sequence 
complementarity between lin-4 (red) and the 3′-untranslated region (UTR) of lin-14 mRNA 
(blue). lin-4 is partially complementary to 7 sites in the lin-14 3′ UTR. RISC, RNA-induced 
silencing complex. (Lin et al., 2004). 
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1.2 miRNAs and siRNAs  
 
Almost coincident with the discovery of the second miRNA, let-7, small RNAs were 
also characterized as components of a seemingly separate biological process, RNA 
interference (RNAi). RNAi is an evolutionarily conserved, sequence-specific gene-
silencing mechanism that is induced by exposure to dsRNA (Hannon, 2002). In 
many systems, including worms, plants and flies, the stimulus that was used to 
initiate RNAi was the introduction of a dsRNA (the trigger) of ~500 bp. The trigger 
is ultimately processed in vivo into small dsRNAs of ~21–25 bp in length, designated 
as small interfering RNAs (siRNAs) (Elbaschir et al., 2001). It is now clear that one 
strand of the siRNA duplex is selectively incorporated into an effector complex (the 
RNA-induced silencing complex; RISC). The RISC directs the cleavage of 
complementary mRNA targets, a process that is also known as post-transcriptional 
gene silencing (PTGS) (Fig. 2) (Zamore et al., 2000). The evolutionarily conserved 
RNAi response to exogenous dsRNA might reflect an endogenous defense 
mechanism against virus infection or parasitic nucleic acids (Hannonet, 2002). 
Indeed, mutations of the RNAi components greatly compromise virus resistance in 
plants, indicating that PTGS might normally mediate the destruction of the viral 
RNAs (Baulcombe, 1999).  In addition, siRNAs can also regulate the expression of 
target transcripts at the transcriptional level, at least in some organisms. Not only can 
siRNAs induce sequence-specific promoter methylation in plants (Aufsatz et al. 
2002; Mette et al., 2000) but they are also crucial for heterochromatin formation in 
fission yeast (Grewal et al, 2003; Volpe et al. 2002) and transposon silencing in 
worms (Ketting et al, 1999; Chen, 2004). Fundamentally, siRNAs and miRNAs are 
similar in terms of their molecular characteristics, biogenesis and effector functions. 
So, the current distinctions between these two species might be arbitrary, and might 
simply reflect the different paths through which they were originally discovered. 
miRNAs and siRNAs share a common RNase-III processing enzyme, Dicer, and 
closely related effector complexes, RISCs, for post-transcriptional repression (Fig. 
2). In fact, much of our current knowledge of the biochemistry of miRNAs stems 
from what we know about siRNAs and the RNAi pathway. On the other hand, 
miRNAs differ from siRNAs in their molecular origins and, in many of the cases that 
have been characterized so far, in their mode of target recognition. miRNAs are 
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produced as a distinct species from a specific precursor that is encoded in the 
genome. The structure of the primary miRNA transcript and the recognition of this 
precursor by a nuclear processing machinery probably determines the sequence and 
structure of mature miRNAs (Bartel, 2004). Conversely, siRNAs are sampled more 
randomly from long dsRNAs that can be introduced exogenously or produced from 
bi-directionally transcribed endogenous RNAs that anneal to form dsRNA (Hannon, 
2002). In many cases, miRNAs bind to the target 3′ UTRs through imperfect 
complementarity at multiple sites, and therefore negatively regulate target expression 
at the translational level. Conversely, siRNAs often form a perfect duplex with their 
targets at only one site, and therefore direct the cleavage of the target mRNAs at the 
site of complementarity (Fig. 2). 
 
                    
 
Figure 2. The current model for the biogenesis and post-transcriptional suppression of 
microRNAs and small interfering RNAs (He et al., 2004). 
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1.3 Biogenesis of microRNA 
 
Early annotation of the genomic position of miRNAs indicated that most miRNAs 
are located in intergenic regions (>1 kb away from annotated/predicted genes), 
although a sizeable minority was found in the intronic regions of known genes in the 
sense or anti-sense orientation (Lau et al., 2001; Lagos-Quintana et al., 2001). This 
led to the postulation that most miRNA genes are transcribed as autonomous 
transcription units. Another interesting observation was that ~50% of known 
miRNAs are found in close proximity to other miRNAs (Lau et al., 2001; Lagos-
Quintana et al., 2001; Mourelatos et al., 2002), which raised the possibility that these 
clustered miRNAs might be transcribed from a single polycistronic transcription 
unit. A detailed analysis of miRNA gene expression showed that miRNA genes can 
be transcribed from their own promoters (Lee et al., 2004; Cai et al., 2004), and that 
the clustered miRNAs are generated as polycistronic primary transcripts (pri-
miRNAs) (Lee et al., 2002). 
A recent analysis showed that miRNAs can be categorized into three groups 
according to their genomic locations relative to their positions in an exon or intron. 
First, exonic miRNA in non-coding transcription units; second, intronic miRNA in 
non-coding transcription units; and third, intronic miRNA in protein-coding 
transcription units. Mixed miRNA genes can be assigned to one of the above groups 
depending on the given splicing pattern (Rodriguez et al, 2004). 
miRNA genes are transcribed by either RNA polymerase II or RNA polymerase III 
into primary miRNA transcripts (pri-miRNA) (Lee et al., 2004; Cai et al., 2004; 
Borchert et al., 2006). 
This primary transcripts that encode miRNAs (pri-miRNAs) contain 5‘ cap structure 
as well as 3‘ poly(A) tails (Lee et al., 2004; Cai et al., 2004). 
The sequential cleavages of miRNA maturation are catalysed by two RNase-III 
enzymes, Drosha and Dicer (Lee et al., 2003; Hutvagner et all., 2001). Both are 
dsRNA-specific endonucleases that generate 2-nucleotide-long 3′ overhangs at the 
cleavage site.  
Drosha form a nuclear microprocessor complex with DGCR8 protein (DiGeorge 
critical region 8) (also known as Pasha in D. melanogaster and C. elegans) (Lee et 
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al., 2003). This complex is predominantly localized in the nucleus and contains two 
tandem RNase-III domains, a dsRNA binding domain and an amino-terminal 
segment of unknown function (Lee et al., 2003).  
Regardless of the diverse primary sequences and structures of pri-miRNAs, Drosha 
cleaves these into ~70-bp pre-miRNAs that consist of an imperfect stem-loop 
structure (Fig. 3) (Lee et al., 2003). Although the precise mechanisms that Drosha 
uses to discriminate miRNA precursors remain unknown, several studies have 
addressed the features of pri-miRNAs that contribute to Drosha cleavage both in 
vitro and in vivo (Lee et al., 2003; Zeng et al., 2003). The efficiency of Drosha 
processing depends on the terminal loop size, the stem structure and the flanking 
sequence of the Drosha cleavage site, because shortening of the terminal loop, 
disruption of complementarity within the stem and removal or mutation of sequences 
that flank the Drosha cleavage site significantly decrease, if not abolish, the Drosha 
processing of pri-miRNAs (Lee et al., 2003; Zeng et al., 2003).  
Drosha-mediated processing of pri-miRNAs into pre-miRNAs is not obligatory. 
Intron-derived miRNAs are released from their host transcripts after splicing (Fig. 3). 
If the intron resulting from the action of the splicing machinery has the appropriate 
size to form a hairpin resembling a pre-miRNA, it bypasses Drosha cleavage and is 
further processed in the cytoplasm by Dicer. These miRNAs, called mirtrons, have 
been discovered in several species including mammals, D. melanogaster and C. 
elegans (Okamura et al., 2007; Ruby et al., 2007; Berezikov et al., 2007). 
After the initial process, pre-miRNAs are exported from the nucleus into the 
cytoplasm by Exportin 5 (Exp5), a Ran-GTP dependent nucleo/cytoplasmic cargo 
transporter (Fig. 3) (Lund et al., 2004). Once inside the cytoplasm, these hairpin 
precursors are cleaved by Dicer into a small, imperfect dsRNA duplex (miRNA: 
miRNA*) that contains both the mature miRNA strand and its complementary strand 
(miRNA*) (Hutvagner et al., 2001; Grishok et al. 2001; Ketting et al., 2001). Dicer 
contains a putative helicase domain, a DUF283 domain, a PAZ (Piwi–Argonaute–
Zwille) domain, two tandem RNase-III domains and a dsRNA-binding domain 
(dsRBD) (Bernstein et al., 2001).  
Following  their processing, miRNAs are assembled into ribonucleoprotein (RNP) 
complexes called micro-RNPs (miRNPs) or miRNA-induced silencing complexes 
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(miRISCs). The assembly is a dynamic process, usually coupled with pre-miRNA 
processing by Dicer. 
The target specificity, and probably also the functional efficiency, of a miRNA 
requires that the mature miRNA strand from the miRNA:miRNA* duplex is 
selectively incorporated into the RISC for target recognition (Schwarz et al., 2003; 
Khvorova et al., 2003). The miRNA* strand, on the other hand, is probably degraded 
rapidly on its exclusion from the RISC, as the recovery rate of miRNA*s from 
endogenous tissues is ~100-fold lower than that of miRNAs (Schwarz et al., 2003). 
As Dicer processes the pre-miRNA into the miRNA:miRNA* duplex, the stability of 
the 5′ ends of the two arms of the miRNA:miRNA* duplex is usually different. 
Although mature miRNAs can reside on either strand of the hairpin stem, it is almost 
always derived from the strand with the less stable 5′ end compared with the 
miRNA* strand (Schwarz et al., 2003; Khvorova et al., 2003). These findings 
indicate that the relative instability at the 5′ end of the mature miRNA might 
facilitate its preferential incorporation into the RISC. The selective assembly of the 
mature miRNA into the RISC probably reflects the relative ease of unwinding from 
one end of the miRNA: miRNA* duplex (Fig. 3) (Schwarz et al., 2003; Khvorova et 
al., 2003). Therefore, the thermodynamic properties of the miRNA precursor 
determine the asymmetrical RISC assembly, and therefore, the target specificity for 
posttranscriptional inhibition. However, in rare cases in which miRNA and miRNA* 
have similar 5′-end stability, each arm of the miRNA precursor is predicted to be 
assembled into the RISC at similar frequencies. This prediction has been confirmed 
by similar recovery rates for such miRNAs and miRNA*s from endogenous tissues 
(Schwarz et al., 2003). This thermodynamic model also applies to the asymmetrical 
assembly of the siRNA duplex, in which the strand of siRNA with the less stable 5′ 
end is preferentially assembled into the RISC complex to target mRNA cleavage 
(Schwarz et al., 2003; Khvorova et al., 2003).  
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Figure 3. Biogenesis of miroRNAs and their assembly into micro-ribonucleo-proteins complex 
(miRNPs) (Filipowicz et al. 2008). 
 
1.4 Mechanism: post-transcriptional repression by miRNA 
 
MicroRNAs function as negative gene regulators in association with  
ribonucleoprotein (RNP) complexes or RISCs (induced silencing complexes).  
The most important and best-characterized components of miRNPs are proteins of 
the Argonaute family. Mammals contain four Argonaute (AGO) proteins, AGO1 to 
AGO4. AGO2 is the only AGO that functions in RNAi because it can cleave mRNA 
at the centre of the siRNA–mRNA duplex. Apart from the AGO proteins, miRNPs 
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often include other proteins, which probably function as miRNP assembly or 
regulatory factors, or as effectors mediating  the repressive miRNP functions (Peters 
et al., 2007; Tolia et al., 2007). 
Today, the molecular mechanism by which miRNP complexes function as repressors 
of protein synthesis are not clear. However, several recently published papers 
provide important mechanistic insights into the miRNP complex repression at the 
different  mRNA translational steps (Filipowicz et al., 2008).  
mRNA translation can be divided into three steps: initiation, elongation and 
termination.  
Initiation starts with the recognition of the mRNA 5′-terminal cap structure 
(m
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GpppN in which N is any nucleotide) by the eIF4e subunit of the eukaryotic 
translation initiation factor (eIF) eIF4F, which also contains eIF4G, an important 
scaffold for the assembly of the ribosome initiation complex. Interaction of eIF4G 
with another initiation factor, eIF3, facilitates the recruitment of the 40S ribosomal 
subunit (Merrick et al. 2004; Kapp et al., 2004).  eIF4G also interacts with the 
polyadenylate-binding protein 1 (PABP1). The ability of eIF4G to interact 
simultaneously with eIF4e and PABP1 brings the two ends of the mRNA in close 
proximity (Wells et al., 1998, Derry et al., 2006). This ‗circularization‘ stimulates 
translation initiation by increasing the affinity of eIF4e for m
7
GpppN, and might 
facilitate ribosome recycling (Derry et al., 2006). Some cellular and viral mRNAs 
initiate translation independently of the m
7
G cap and eIF4e; in this case, 40S 
ribosomes are recruited to the mRNA through interaction with an 
internal ribosome entry site (IRES) (Jackson et al., 2005). Joining of the 60S subunit 
at the AUG codon precedes the elongation phase of translation. 
The investigations revealed that the translation of m
7
G-capped mRNAs, but not of 
mRNAs containing an IRES, is repressed by miRNAs (Pillai et al., 2005; Humphreys 
et al., 2005). 
There is substantial evidence that factors bound at the 3′ UTR exert their inhibitory 
effect on translational initiation by recruiting proteins that either interfere with the 
eIF4E–eIF4G interaction or bind directly to the cap but, unlike eIF4e, are unable to 
associate with eIF4G and promote assembly of the 40S initiation complex 
(Chekulaeva et al., 2006; Richter et al., 2005; Cho et al., 2005). Kiriakidou et al. 
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recently reported that the central domain of AGO proteins contains limited sequence 
homology to the cap-binding region of eIF4e. These data indicate that AGO2 and 
related proteins can compete with eIF4e for m
7
G binding and thus prevent translation 
of capped, but not IRES-containing, mRNAs (Kiriakidou et al., 2007).  
An alternative mechanism of miRNA action was recently proposed by Chendrimada 
et al. The authors reported that eIF6 and 60S ribosomal subunit proteins co-
immunoprecipitate with the mRNPs complex. eIF6 was first described as a protein 
that binds the 60S subunit to prevent its precocious interaction with the 40S subunit 
(Russell et al., 1978), and was thought to act as an initiation factor. However, it was 
shown later that eIF6 is not involved in translation in yeast, but rather has a crucial 
function (both in yeast and mammals) in the biogenesis of the 60S subunit in the 
nucleolus, and accompanies the 60S subunit to the cytoplasm (Sanvito et al., 1999; Si 
et al., 1999; Basu  et al., 2001). Chendrimada et al. showed that partial depletion of 
eIF6 in either human cells or C. elegans rescues mRNA targets from miRNA 
inhibition, possibly by reducing eIF6-mediated impediment of 60S joining 
(Chendrimada et al., 2007).  
Although initial studies suggested that the levels of miRNA-inhibited mRNAs 
remain mostly unchanged, more recent work has demonstrated that the repression of 
many miRNA targets is frequently associated with their destabilization (Wu et al., 
2006; Bagga et al., 2005; Behm-Ansmant et al., 2006; Giraldez et al., 2006; Wu et 
al., 2005). In eukaryotes, mRNA degradation can follow two pathways, each of 
which is initiated by a gradual shortening of the mRNA poly(A) tail. The mRNA 
body can then be degraded by progressive 3′→5′ decay, which is catalysed by the 
exosome, or by the removal of the cap followed by 5′→3′ degradation, which is 
catalysed by the exonuclease. Levels of mRNA are controlled by mRNPs through the 
recruitment of decay machinery components, leading to mRNA deadenylation and 
decapping. The degradation, or at least its final steps, is thought to occur in P-bodies, 
cellular structures that are enriched in mRNA-catabolizing enzymes and translational 
repressors (Eulalio et al., 2007; Parker et al., 2007). The mechanism of miRNA-
mediated mRNA destabilization is best understood in D. melanogaster. Studies in D. 
melanogaster S2 cells demonstrated that the P-body protein GW182 (protein that 
recruits the CCR4–NOT deadenylation complex to the miRNA-bound mRNA), 
12 
which interacts with the miRNP Argonaute1, is a key factor that marks mRNAs for 
decay (Behm-Ansmant et al., 2006).   
On the basis of many lines of evidence, it is widely believed that miRNAs suppress 
protein synthesis by different mechanism. 
                                                                                                                                                                                                                        
1.5 Target recognition: interaction miRNA-mRNA 
 
MicroRNAs interact with their mRNA targets by base pairing. In plants, most 
miRNAs base pair to mRNAs with nearly perfect complementarity and induce 
mRNA degradation by an RNAi-like mechanism: the mRNA is cleaved 
endonucleolytically in the middle of the miRNA- mRNA duplex (Jones-Rhoades et 
al., 2006). By contrast, with few exceptions, mammalian miRNAs base pair with 
their targets imperfectly, following a set of rules that have been identified by 
experimental and bioinformatics analyses (Doench et al., 2004; Brennecke et al., 
2005; Lewis et al., 2005; Grimson et al., 2007; Nielsen et al., 2007). 
One rule for miRNA–target base paring is perfect and contiguous base pairing of 
miRNA nucleotides 2 to 8, representing the ‗seed‘ region (Fig. 4, shown in dark red 
and green), which nucleates the miRNA–mRNA association. G:U pairs or 
mismatches and bulges in the seed region greatly affect repression. However, an A 
residue across position 1 of the miRNA, and an A or U across position 9 (Fig. 4, 
shown in yellow), improve the site efficiency, although they do not need to base pair 
with miRNA nucleotides. 
Another rule is that bulges or mismatches must be present in the central region of the 
miRNA–mRNA duplex, precluding the Argonaute (AGO)-mediated endonucleolytic 
cleavage of mRNA. 
The third rule is that there must be reasonable complementarity to the miRNA 3′ half 
to stabilize the interaction. Mismatches and bulges are generally tolerated in this 
region, although good base pairing, particularly to residues 13–16 of the miRNA 
(Fig. 4 , shown in orange), becomes important when matching in the seed region is 
suboptimal (Brennecke et al., 2005; Lewis et al., 2005; Grimson et al., 2007). 
Other factors that can improve site efficacy include an AU-rich neighborhood and, 
for long 3′ UTRs, a position that is not too far away from the poly(A) tail or the 
termination codon; these factors can make the 3′ UTR regions less structured and 
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hence more accessible to miRNP recognition (Grimson et al., 2007; Nielsen et al., 
2007; Gaidatzis et al., 2007). Indeed, accessibility of binding sites might have an 
important effect on miRNA-mediated repression (Kerteszet al., 2007). Some 
experimentally characterized sites deviate significantly from these rules and can, for 
example, even require a bulged nucleotide in the seed region pairing. In addition, 
combinations of sites can require a specific configuration (for example, separation by 
a stretch of nucleotides of specific sequence and length) for efficient repression 
(Velle et al., 2004). Usually, miRNA-binding sites in mammalian mRNAs lie in the 
3′ UTR and are present in multiple copies. Importantly, multiple sites for the same or 
different miRNAs are generally required for effective repression. When they are 
present close to each other (10–40 nucleotides apart) they tend to act cooperatively, 
that is, their effect exceeds that expected from the independent contributions of two 
single sites (Doench et al., 2004; Brennecke et al., 2005; Lewis et al., 2005; Grimson 
et al., 2007; Nielsen et al., 2007). 
 
 
 
Figure 4. Principles of microRNA–mRNA interactions (Filipowicz et al. 2008). 
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2. MicroRNAs and Cancer  
 
The ‗classic‘ view of molecular oncology indicates that cancer is a genetic disease 
involving tumor suppressor and oncogenic proteins. However, in the recent years, it 
has been demonstrated that miRNAs are involved in human tumorigenesis, thus 
revealing a new layer in the molecular architecture of human cancer. Gene 
expression studies revealed that hundreds of miRNAs are deregulated in cancer cells 
and functional studies clarified that miRNAs are involved in all the molecular and 
biological processes that drive tumorigenesis (Negrini et al, 2009). 
The mechanisms by which miRNA expression is altered in cancer are multifaceted. 
The function of miRNAs in cancer seems to be disrupted by the same mechanisms as 
those that affect the expression of protein-encoding genes (amplifications, 
translocations, deletions, and point mutations of the pri-miRNA-encoding DNA 
sequence) and by epigenetic disruption of miRNA transcription (Calin et al., 2006). 
Abnormal miRNA function in cancer can be explained by different mechanisms:  
mutation in miRNAs, epigenetic regulation of miRNA expression, miRNAs 
localization at translocation breakpoint, change in the miRNAs processing apparatus,  
sequence variation in the miRNA-mRNA binding sites. 
A genome-wide study proved that half of the annotated human miRNAs are located 
in cancer-associated-genomic-regions (CAGRS). Such regions include minimal 
regions of LOH (loss-of-heterozygosity), which are thought to harbour tumour-
suppressor genes, minimal regions of amplification, which might contain oncogenes, 
common breakpoint regions in or near possible oncogenes or tumour-suppressor 
genes and fragile sites (FRA). FRA are preferential sites of sister-chromatid 
exchange, translocation, deletion, amplification or integration of plasmid DNA and 
tumour-associated viruses such as human papilloma virus (HPV) (Calin et al., 2004). 
An example of  miRNAs that are located in chromosomal regions showing LOH in 
cancer, are miR-15 and -16 in CLL. A germ-line mutation was observed in the miR-
16-1-miR-15a pri-miRNA, and the presence of this mutation correlated with low 
miRNA expression and deletion of the second allele. The exact mechanism whereby 
this is mediated is unclear; however, it was suggested that the mutations affect the 
miRNA hairpin formation. Many (73%) of the patients with mutant miRNAs had a 
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family history of CLL or other cancers, this led to the hypothesis that miRNA gene 
mutations might play a major role in cancer (Diederichs et al., 2006).  
DNA hypomethylation, CpG island hypermethylation and histone-modification 
losses represent epigenetic markers of malignant transformation (Fraga et al., 2005). 
Several groups have investigated whether such events also affect miRNA expression. 
Furthermore, Saito et al. found that the combined treatment of human bladder cancer 
cells with 5-aza-2′-deoxycytidine (5-Aza-CdR) and the histone deacetylase (HDAC) 
inhibitor 4-phenylbutyric acid (PBA) has a significant effect on the expression of 
miRNAs (Saito et al., 2006). Seventeen miRNAs (out of 313 screened by a 
microarray assay) were upregulated more than threefold, and miR-127 was the most 
differentially expressed. This miRNA is located in a CpG island at chromosome 
14q32, a region that is involved in several types of translocations identified in 
haematological cancers and deleted by LOH in solid tumours (Calin et al., 2004). 
Furthermore, the combined treatment was accompanied by a decrease in DNA 
methylation and an increase in active histone markers around the transcription start 
site of miR-127. The investigators showed that miR-127 can repress the transcription 
of the zinc-finger repressor BCL6. BCL6 is a proto-oncogene upregulated in a large 
proportion of B-cell lymphomas, where it acts as a transcriptional suppressor of 
TP53 and downstream effectors of TP53. The induction of miR-127 by 5-Aza-CdR 
and PBA treatment in cancer cells might have an anticancer effect by down-
regulating anti-apoptotic factors, such as BCL6, and inducing apoptosis (Saito et al., 
2006). In another study a number of miRNAs are upregulated in the 
DNMT1/DNMT3b (DNA methyltransferase 1 and 3b) double knockout (DKO) cells. 
The miR-124a was selected from this panel, and further studies showed that it was 
inactivated by promoter methylation in a variety of tumors, including colon-, breast-, 
lung-, and hematopoietic cancers. One oncogenic target of this miRNA is the cell 
cycle regulator cyclin-dependent kinase 6 (CDK6), which accelerates cell cycle 
progression through the G1/S checkpoint by phosphorylating Rb. Indeed, 
hypermethylation of miR-124a correlated with CDK6 activation and Rb 
phosphorylation in this study (Lujambio et al., 2007). 
Several observations document the presence of miRNAs at chromosomal 
breakpoints, suggesting their role as translocation partners. The classical example is 
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the translocation of the miR-142 to the MYC oncogene in the t(8;17). In analogy to 
the translocations of MYC to the immunoglobulin gene locus, this translocation 
brings MYC under the control of the miR-142 gene promoter, which leads to its 
upregulation in aggressive B-cell lymphoma (Lagos-Quintana et al., 2002). Other 
indications of a role for miRNAs in translocations include the observation that the 
pri-miR-122a gene is located at chromosome 18 near the MALT1 gene, which is 
involved in translocations of the majority of mucosa-associated lymphoid tissue 
(Calin et al., 2004). Furthermore, insertion of the miR-125b into the rearranged 
immunoglobulin heavy (IgH) chain gene locus, has been demonstrated in a case of 
precursor B-cell acute lymphoblastic leukemia. Since most translocations in B-cell 
tumors involve the IgH-locus, this observation may further support a role for 
miRNAs at translocation breakpoints (Sonoki T et al., 2005). 
The protein machinery that is involved in the biogenesis of miRNAs is complex, 
alterations of these proteins should have dramatic effects on miRNA expression.  In 
fact, expression of Dicer has been shown to be down-regulated in lung cancer. 
Karube et al. examined RNA expression levels of DICER and DROSHA in 67 non-
small-cell lung cancer samples. They found that reduced expression of DICER 
correlates with shortened post-operative survival, which indicates that Dicer might be 
able to prevent the transformation of lung tissue. As Dicer has been implicated in 
heterochromatin maintenance and centromeric silencing, reduced protein levels 
might directly result in genomic instability and lead to tumour formation (Karube et 
al, 2005; Fukagawa et al., 2004). 
Finally, inappropriate base pairing due to variations in the 3‘-UTR sequence of the 
target mRNAs or in the mature miRNA sequence may be another mechanism of 
miRNA functional disruption in cancer. Tumors may evade growth inhibition by 
tumor-suppressor-miRNAs if they do not bind properly to their target oncogenic 
mRNA sequence, or alternatively, tumor growth may be enhanced by sequence 
variations that promote the binding properties of oncomiRs to tumor suppressor 
mRNAs. Loss of the KIT protein in thyroid cancers has been associated with high 
expression of the miRs -221, -222, and -146b, and polymorphic changes in 3‘-UTR 
of the KIT-mRNA were demonstrated in half of these cases (He et al., 2005). Owing 
to the high incidence of familial thyroid cancer, it was speculated whether these 
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polymorphisms might predispose to this disease. Polymorphic changes in the mature 
miRNA sequences have also been observed. For example, a sequence variation that 
may alter the target selection has been identified in the mature miR-30c-2, which is 
overexpressed in many solid tumors (Iwai et al., 2005). 
 
2.1 Onco-miRNA and tumor-suppressor-miRNA. 
 
A number of miRNAs have been shown to promote cell proliferation and survival, 
while others diminish cell proliferation and survival. These two classes of miRNAs 
may play a central role in cancer development as novel oncogenes and tumor 
suppressors, respectively. In normal tissues, some of these miRNAs have been 
documented to inhibit the translation of proto-oncogenes by targeting the 3‘UTR of 
their mRNAs. Such miRNAs are therefore considered as ‗‗tumor suppressor 
miRNAs‘‘ since their normal function is to control the expression of an oncogene. 
Conversely, certain miRNAs seem to be upregulated in cancer and may act as 
‗‗oncomiRs‘‘, as they can enable the downregulation of a tumor suppressor. Since 
miRNAs have several potential targets that may be the mRNAs of both oncogenes 
and tumor suppressors, the actual function of a particular miRNA as either tumor 
suppressor miRNA or onco-miR may depend on the cellular context (Esquela-
Kerscher et al., 2006). 
The first indication that miRNAs could function as tumour suppressors came from a 
report by Calin et al. that showed that patients who were diagnosed with a common 
form of adult leukaemia, B-cell chronic lymphocytic leukemia (CLL), often have 
deletions or downregulation of two clustered miRNA genes, mir-15a and mir-16-1 
(Calin et al., 2002). Deletions within the 13q14 locus occur in more than 65% of 
CLL cases, as well as in 50% of mantle cell lymphomas, 16–40% of multiple 
myelomas and 60% of prostate cancers. Therefore, it was predicted that a tumour-
suppressor gene must reside in this 30-kb region. Interestingly, mir-15a and mir-16-1 
map within the intron of a non-protein-coding RNA gene of unknown function, 
which is called LEU2 . Subsequently, a report by Cimmino et al. showed that miR-
15a and miR-16-1 negatively regulate BCL2, an anti-apoptotic gene that is often 
overexpressed in many types of human cancers, including leukaemias and 
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lymphomas (Cimmino et al., 2005). Therefore, it is thought that the deletion or 
downregulation of mir-15a and mir-16-1 results in increased expression of BCL2, 
promoting leukaemogenesis and lymphomagenesis in haematopoietic cells. The 
tumour-suppressor role of miR-16 was further supported by the finding that two 
patients with CLL carried a germline C to T mutation 7 base-pairs downstream of the 
mir-16-1 precursor, resulting in decreased miR-16-1 expression levels (Calin et al., 
2005). 
Another early and well-documented finding was the down-regulation of oncogenic 
Ras by the let-7 family members of miRNAs in lung cancer (Johnson et al., 2005). 
Ras proteins are membrane-associated GTPase signalling proteins that regulate 
cellular growth and differentiation. About 15–30% of human tumours possess 
mutations in Ras genes and activating mutations that result in the increased 
expression of Ras cause cellular transformation.  The miRNAs that are encoded by 
the let-7 family, which include 12 human homologues, were implicated as tumour 
suppressors because they map to fragile sites associated with lung, breast, urothelial 
and cervical cancers (Calin et al., 2004). More direct evidence, presented by 
Takamizawa et al., showed that transcripts of certain let-7 homologues were 
significantly downregulated in human lung cancer and that this correlated with a 
poor prognosis (Takamizawa et al., 2004).  These studies further indicate that let-7 
could be used diagnostically, as patients with non-small-cell lung carcinomas who 
expressed lower levels of let-7 had a poorer prognosis and shortened post-operative 
survival. Successive study found that let-7 negatively regulates Ras in human cells. 
In fact, overexpression of let-7 in human cancer cell lines results in decreased levels 
of Ras compared with untreated cells. Conversely, the depletion of RNA levels of 
let-7 in human cancer cell lines that normally express high levels leads to a marked 
increase in Ras protein expression. let-7 directly controls Ras expression through 3′-
UTR mediated repression in human cells (Johnson et al., 2005; Esquela-Kerscher et 
al., 2008).  
Several studies have implicated other miRNAs in tumorigenesis. miR-143 and miR-
145 have been shown to be constantly down-regulated in colorectal tumors (Michael 
et al., 2003) and breast cancer (Iorio et al., 2005). Moreover, the location of these 
miRNAs is known to be in a genomic locus frequently 
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deleted in myelodysplastic syndrome (Calin et al, 2004). Some studies have ascribed 
the down-regulation of miR-143 and miR-145 in colon cancer to a block in Dicer 
processing (Michael et al., 2003). 
In contrast to tumor-suppressor-miRNAs, oncomiRs are frequently upregulated in 
cancers and show proliferative and anti-apoptotic activity. One of the first oncomiRs 
to be identified was miR-155, which is co-expressed with the non-protein-coding 
gene BIC. This gene was initially identified as a common integration site for the 
avian leukosis virus and was found to be overexpressed in B-cell lymphomas 
(Clurman et al. 1989; Tam et al., 1997). For years, researchers were puzzled as to 
how an RNA that was presumably not protein-coding, and was poorly conserved 
between avian, mouse and human genomes, could promote lymphomas in cells that 
also overexpressed MYC. Metzler et al. showed that miR-155 expression is 
upregulated 100-fold in pediatric Burkitt lymphoma, and other studies showed 
increased miR-155 levels in Hodgkin lymphoma and in primary mediastinal and 
diffuse large-B-cell lymphomas with activated rather than germinal-centre 
phenotypes  (Metzler et al., 2004; Eis et al., 2005). Therefore, it seems that mir-155 
can function as an oncogene in cooperation with MYC, whereas it normally functions 
during B-cell selection and possibly targets genes that antagonize the MYC pathway. 
The members of the miR-17-92 cluster represent another intensely studied group of 
potential oncomiRs that are frequently upregulated in lymphomas. This cluster 
consists of seven individual miRNAs: miR-17-5p, 17-3p, -18, -19a,-19b1, -20, and 
92, which are all encoded from a frequently amplified locus at 13q31.3 (Hayashita et 
al., 2005; Ota et al., 2004). It was shown in MYC transgenic mice that the miR-17-92 
cluster overexpression, but not the individual miRNAs, could enhance tumorigenesis 
by inhibiting  apoptosis,  as compared with the latent malignancies that arose from 
increased MYC expression levels alone. (He et al, 2005). Further studies in human 
cell lines showed that transcription of the miR-17-92 cluster was directly regulated 
by c-Myc, and that the individual miRs -17-5p and -20 regulate the  translation of 
E2F1, a transcription factor with both pro-apoptotic and pro-proliferative activity. 
Thus, co-expression of c-Myc and miR-17 is believed to fine tune E2F1 activity so 
that proliferation is enhanced and apoptosis is inhibited (O‘Donnell et al., 2005). 
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Anti-apoptotic activity has also been documented to be a feature of miR-21, one of 
the most frequently upregulated miRNAs in solid tumors (glioblastoma, breast, 
colon, lung, pancreas, prostate and stomach) (Chan et al., 2005; Volinia et al., 2006). 
As recently shown, miRNA-21 also participates in RAS oncogenic signaling. miR-21 
is transcriptionally induced by AP1 downstream of RAS and exerts its oncogenic 
effect by keeping in check PTEN and PDCD4 (Si et al. 2007; Talotta et al., 2009). 
Finally, various studies have reported that miRNAs are also aberrantly expressed in 
brain tumors. During the analysis of a global expression level of 245 miRNAs in 
glioblastoma multiforme, Ciafre et al. (2005) observed that miR-221 was highly 
upregulated. In a recent work, Gillies and Lorimer (2007) have reported that miR-
221and miR-222 directly target p27
Kip1
, a key negative regulator of the cell cycle, in 
glioblastoma. 
 
2.2 miRNA profiling in cancer 
 
Multiple lines of evidence indicating that miRNAs are differentially expressed in 
normal and in tumor samples suggesting that miRNAs could serve as useful tumor 
profiling tools. Indeed, profiling studies have shown that each cancer type possesses 
a distinct miRNA expression signature, and this signature can provide useful 
information about the malignancy. The adaptation of high-throughput technologies 
have facilitated the study of the expression of multiple miRNAs in a given sample, 
making it possible to profile substantial sample numbers with relative ease. Among 
the most important methods for miRNA profiling is the use of oligonucleotide 
miRNA microarray analysis, which allows the researcher to simultaneously 
determine the expression levels of hundreds of miRNAs in a given sample (Kim et 
al., 2006; Liu et al., 2004; Hammond et al., 2006). Another method to determine 
miRNA expression levels involves the use of a bead-based flow-cytometric 
technique (Lu et al., 2005). Other developments include quantitative real-time PCR 
for precursor miRNAs (Schmittgen et al. 2004) or active miRNAs (Chen et al. 2005; 
Raymond et al., 2005), miRAGE (a genome-wide miRNA analysis with serial 
analysis of gene expression SAGE) (Cummins et al. 2006) or the high-throughput 
array-based Klenow enzyme (RAKE) assay (Nelson et al., 2004). Taking advantage 
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of these tools, several groups have studied the miRNA expression of several types of 
cancer. 
Using a bead-based miRNA microarray assay, Lu et al. conducted the expression 
analysis of 217 miRNAs in a panel of 334 samples that included primary tumors, 
tumor-derived cell lines and normal tissues. The investigators found that miRNA 
profiles can distinguish between normal and cancer tissues, separate different cancer 
types, stratify the cancer differentiation state and cluster sample groups according to 
their embryonic lineage. Moreover, miRNA profiles were more accurate than mRNA 
profiles in classifying tumor types and were able to categorize 17 poorly 
differentiated tumors where histological appearance was not diagnostic into their 
specific tissue lineages (Lu et al., 2005).  
Studying colorectal cancer, Michael et al. were the first to recognize aberrant 
miRNA expression in solid tumors as the investigators identified 28 different 
miRNAs in colonic adenocarcinoma and normal mucosa, and found that miR-143 
and miR-145 were consistently downregulated in cancer (Michael et al., 2003). 
Bloomston et al. showed that a signature of 21 upregulated and 4 downregulated 
miRNAs correctly differentiated pancreatic cancer from benign pancreatic tissue in 
90% of samples. In the profile, two commonly malignancy associated miRNAs, 
miR-21 and miR-155, were uniquely overexpressed in pancreatic cancer compared to 
normal pancreas (Bloomston et al., 2007).  
Of significant importance is a study performed by Rosenfeld et al., which needed 
only 48 miRNA markers to identify 22 tissue origins with an accuracy of 90% 
(Rosenfeld et al., 2008). This work holds promise for the 3–5% of patients from all 
new cancer cases diagnosed with metastatic cancer of unknown primary origin 
(Pimiento et al., 2007). Enabling oncologists to identify the tissue of origin will 
markedly improve treatment decision and prognosis. 
Recently, a very new and exciting venue of potential cancer diagnosis has emerged 
through the detection of miRNAs in serum. In one of the first reports of this method, 
Lawrie et al. showed that sera levels of miR-21 were associated with relapse-free 
survival in patients with diffuse large B-cell lymphoma (Lawrie et al., 2008). In 
another study, Mitchell et al. showed that miRNAs can enter the circulation even 
when they originate from an epithelial cancer cell type. The investigators found that 
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serum levels of miR-141 can distinguish patients with prostate cancer from healthy 
subjects (Mitchell et al., 2008). Other two groups were able to identify functional 
miRNAs in circulating tumor exosomes with specific miRNA signature discerning 
patients with ovarian and lung cancers from healthy controls (Taylor and Gercel-
Taylor, 2008; Rabinowits et al., 2009).  
One continuing concern for oncologists is giving patients the right prognosis and 
being able to predict the outcome for certain types of cancer. Several studies 
profiling the different levels of Dicer and Drosha and miRNAs between normal and 
tumor tissues were able to shed some light on this problem. A recent study, showed 
that levels of the miRNA-processing enzymes Drosha and Dicer were able to predict 
survival in ovarian cancer, with low level of Dicer associated with advanced tumor 
stage, reduced response to chemotherapy and poor clinical outcome. Low levels of 
Drosha are associated with suboptimal surgical cytoreduction, a poor prognostic 
factor. High levels of Dicer and Drosha are associated with increased median 
survival (Merritt et al., 2008). In a lung cancer outcome study, expression levels of 
DICER and DROSHA in 67 non-small-cell lung cancer (NSCLC) samples were 
examined and reduced expression of DICER were correlated with shortened 
postoperative survival (Karube et al., 2005). 
 
2.3 miRNA in cancer therapy 
 
The revealing role of miRNAs functioning as potential oncogenes and tumor 
suppressors in tumorigenesis has generated great interest in using them as targets for 
cancer therapies. In general therapeutic strategies consist of an antisense-mediated 
inhibition of oncogenic miRNAs and miRNA replacement with miRNA mimetics or 
viral vector-encoded miRNAs. 
Synthetic anti-miRNA oligonucleotides (AMOs) with 2‘-O-methyl modification 
have been shown to be effective inhibitors of endogenous miRNAs in cell culture 
and xenograft mice models. Application of 2‘-O-methyl AMOs targeting the onco-
miR-21 potently inhibited glioblastoma and breast cancer cell growth in vitro and 
tumor growth in an MCF-7 breast cancer xenograft mice model (Chan et al., 2005; Si 
et al., 2007). As one of the first studies illustrating the utility of AMOs in vivo, 
modified AMOs conjugated with cholesterol termed ‗antagomirs‘ were 
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systematically delivered through intravenous injection to target the liver-specific 
miR-122 (Krutzfeldt et al., 2005). Impressively, a single injection of 240 mg/kg body 
weight conferred specific miR-122 silencing for up to 23 days. Moreover, as miR-
122 was predicted to affect cholesterol biosynthesis (Krutzfeldt et al., 2005; Esau et 
al., 2006), the serum cholesterol level was seen to decrease by 44% in antagomir-
treated mice. As an alternative to 2‘-hydroxyl-modified AMOs, lock nucleic acid 
(LNA)-based oligonucleotides (LNA-antimiR) have been shown to be more stable 
and less toxic in inhibiting endogenous miRNAs in vivo (Vester and Wengel, 2004; 
Elmen et al., 2008). In this study, systemic administration by intravenous injections 
at a dose of 3 or 10 mg/kg LNA-antimiR to African green monkeys with three 
intravenous infusions over 5 days resulted in the depletion of mature miR-122 and a 
dose-dependent and long-lasting lowering of plasma cholesterol for up to 3 months 
(Elmen et al., 2008).  
In an alternative strategy to single anti-miRs, Ebert et al. recently developed miRNA 
inhibitors called ‗miRNA sponges‘, which can be transiently expressed in cultured 
cells. These molecules are transcripts expressed from strong promoters, containing 
multiple tandem binding sites to specific miRNAs, and competitively inhibit them 
(Ebert et al., 2007). Similarly, Gentner et al. recently illustrated that the stable 
knockdown of miRNA in vivo can be achieved through the construction of lentiviral 
vectors carrying multiple complementary binding sites for the targeted miRNA 
acting as an anti-miRNA decoy (Gentner et al., 2009). In this study, the authors 
retransplanted hematopoietic stem cells carrying lentiviruses expressing the anti-
miR-223 decoy into lethally irradiated mice, which resulted in the functional 
knockdown of miR-223 that phenocopied important aspects of the mouse miR-223 
knockout (Johnnidis et al., 2008). One advantage of these systems is that one could 
construct sponges and anti-miRNA decoys with a combination of miRNA binding 
sites to potentially inhibit an entire miRNA family or an miRNA cluster. 
With anti-miRNA strategies showing great therapeutic promise, the reverse approach 
of miRNA replacement may be equally attractive for anticancer therapy. To examine 
the therapeutic potential of let-7 miRNA replacement in NSCLC, Esquela-Kerscher 
et al., previously examined two murine models of human lung cancer, a xenograft 
model using human lung cancer cells and a well characterized autochthonous 
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NSCLC mouse model, LSL-Kras-G12D. In this mouse model, tumorigenesis is 
initiated by the activation of a gain-of-function Kras G12D gene through the 
inhalation of adenovirus expressing Cre recombinase (Jackson et al., 2001). Using 
these models, they showed that let-7 administration suppresses lung tumor initiation, 
including a 66% reduction of the tumor burden when comparing Kras G12D mice 
treated with adenovirus expressing let-7 miRNA with those that were treated with a 
control miRNA (Esquela-Kerscher et al., 2008).  Similar findings were made by 
Jack‘s lab (Kumar et al., 2008). Since in both studies let-7 miRNA was delivered at 
the same time as tumorigenesis was initiated, these two studies showed 
that let-7 can be used as a preventive therapy against lung cancer in the LSL-Kras 
G12D mice.  
Finally, in a very recent work, Mendell and colleagues showed that the systemic 
delivery of a single miRNA can cause tumors from a mice model of liver cancer to 
regress (Kota et al., 2009). In this study, Kota et al. delivered adeno-associated virus 
8 (AAV8)-expressing miR-26a intravenously through the tail veins of MYC induced 
mice harboring preformed liver tumors. The authors showed that 3 weeks after 
AAV8 infection, they observed a significant regression of tumors in mice receiving 
the miR-26a treatment compared with mice to which the control treatment was 
geven. The result from this study is exciting, as the ability to treat existing tumors 
closely reflects clinical scenarios. Furthermore, has been demostrated that a single 
miRNA is powerful enough to have a dramatic suppression of tumor progression. 
The use of miRNA therapy to complement traditional anticancer treatments appears 
to have great potential, as it has been reported by several groups that miRNAs can 
enhance the response and suppress resistance to anticancer cytotoxic therapies. Meng 
et al. reported the use of anti-miR-21 and anti-miR-200b AMOs to increase the 
susceptibility of colangiocarcinoma cells to the chemotherapy drug gemcitabine 
(Meng et al., 2006). MiR-200c levels were reported to be high in well-differentiated 
endometrial, breast and ovarian cancer cell lines, but extremely low in poorly 
differentiated cancer cells and restoration of miR-200c in these cells increases their 
sensitivity to microtubule-targeting agents by 85% (Cochrane et al., 2009). 
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3. Colon cancer  
 
Colorectal cancer is the third most common type of cancer and the second leading 
cause of cancer related death in the Western world, causing 655,000 deaths 
worldwide per year (Jemal et al, 2006). The incidence of colon cancer is usually 
increased in developed countries, being seemingly linked with a sedentary lifestyle 
and a high caloric intake. The occurrence of colon cancer is slightly higher in men 
than in women and increases with age. Most cases occur between the sixth and the 
seventh decade of life, while cases before age 50 are uncommon, unless a family 
history of early colon cancer is present. Colorectal cancer originates from epithelial 
cells lining the gastrointestinal tract, which undergo sequential mutations in specific 
DNA sequences that disrupt normal mechanisms of proliferation and self-renewal. 
Such mutations, which can derive by inborn genetic aberrations, tobacco smoking, 
environmental carcinogens and chronic inflammatory states, drive the transition from 
healthy colonic epithelia to colorectal cancer. (Ricci-Vitiani et al., 2008)  
The disease begins as a benign adenomatous polyp, which develops into an advanced 
adenoma with high-grade dysplasia and then progresses to an invasive cancer 
(Kinzler et al., 2002). Invasive cancers that are confined within the wall of the colon 
(tumor–node–metastasis stages I and II) are curable, but if untreated, they spread to 
regional lymph nodes (stage III) and then metastasize to distant sites (stage IV). 
Stage I and II tumors are curable by surgical excision, and up to 73% of cases of 
stage III disease are curable by surgery combined with adjuvant chemotherapy. 
Recent advances in chemotherapy have improved survival, but stage IV disease is 
usually incurable (Libutti et al., 2008; Compton et al., 2008). 
 
3.1 Colonic crypt organization. 
 
The colon is organized into four histologically distinct layers. The epithelial layer, at 
the luminal surface, consists of a single sheet of columnar epithelial cells folded into 
finger-like invaginations that are supported by the lamina propria to form the 
functional unit of the intestine called crypts of Lieberkühn (Fig. 5a). Approximately 
14,000 crypts per square centimeter are located in the adult human colon. Given a 
rate of 5 days for colonic epithelium renewal, it has been estimated that over 6×10
14
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colonocytes are produced during the individual lifetime (Pottenet al., 1992). The 
terminally differentiated cells, which are found in the top third of the crypt, are 
continually extruded into the lumen. They are derived from multipotent stem cells 
located at the bottom of the crypt. During asymmetric division, these cells undergo 
self-renewal and generate a population of transit-amplifying cells that, upon 
migration upward the crypt, proliferate and differentiate into one of the epithelial cell 
types of the intestinal wall. There are three major terminally differentiated epithelial 
lineages in the colon: the colonocytes, also termed absorptive enterocytes; the 
mucus-secreting goblet cells; and the less abundant enteroendocrine cells (Fig. 5b). 
Finally, Paneth cells, functionally similar to neutrophils, are scattered at the bottom 
of the crypt only in the small intestine epithelium and do not follow the downward 
migratory pathway. Transit-amplifying cells and stem cells occupy the lower two 
thirds of the crypt (Radtke et al, 2005). The maintenance of the stem cell 
compartment as well as the transition from proliferation to differentiation are finely 
regulated by Wnt signaling ligands that are thought to be produced by mesenchymal 
cells of the myofibroblast lineage, closely applied to the basal lamina that surrounds 
the crypt (Fevr et al., 2007). Other factors, such as the bone morphogenetic protein 
(BMP) antagonists gremlin 1 (GREM1) and gremlin 2 (GREM2) (Kosinski et al., 
2007), Notch signaling pathways, ephrin-B1 (Eph-B1) and its receptors Eph-B2 and 
Eph-B3, contribute to stem cell behavior, migration, and differentiation (van Es et 
al., 2005; Batlle et al., 2002). 
27 
 
 
Figure 5. a) Morphological colon crypt organization unit. b) Schematic description of the different 
cell types in colon epithelium (Crosnier et al., 2006). 
 
3.2  Molecular pathways in colon development 
 
The homeostatic self-renewal of the intestine depends on a complex network of 
interplay involving many cellular processes, including proliferation, differentiation, 
migration, and cell death. All these phenomena are finely regulated by a relative 
small number of evolutionary highly conserved signaling pathways, among which 
the Wnt signaling cascade plays a major role (Fig. 6). In the so-called canonical Wnt 
pathway, the central player is the cytoplasmic protein β-catenin. In the absence of the 
Wnt ligand, free cytoplasmic β-catenin is targeted to degradation by recruitment to a 
multiprotein degradation complex containing the scaffold protein Axin, the tumor 
suppressor gene product adenomatous polyposis coli (APC), as well as casein kinase 
I (CKI) and glycogen synthase kinase 3β (GSK3β). Upon sequential phosphorylation 
of highly conserved serine and threonine residues at the N terminus domain, β-
catenin is ubiquitinated and subsequently degraded by the proteasome machinery. In 
the presence of secreted Wnt ligand, signal occurs via interaction with a serpentine 
receptor of the frizzled (Fz) family and a member of the low-density lipid receptor 
family (Lpr5 or Lpr6). Following binding, Axin is recruited to the plasma membrane 
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through direct interaction with Lpr5/6 or indirectly through an interaction with Fz via 
disheveled (Dsh). Membrane docking results in Axin degradation and/or dissociation 
of the ―destruction complex.‖ GSK3β also might be displaced from this complex 
through Dsh action. Consequently, β-catenin accumulates in the cytoplasm in a 
stabilized non-phosphorylated form, enters the nucleus, and binds to a member of the 
Tcf/Lef family converting the Tcf/Lef transcription factors from transcriptional 
repressors to activators (Gregorieff et al., 2005). Several genetic studies have 
indicated the dominant role of the Wnt signaling pathway in the pathophysiology of 
the intestine. Tcf4 or β-catenin knockout mice fail to develop colonic crypts (Korinek 
et al., 1998; Pinto et al., 2003), as do transgenic mice for the expression of Wnt-
specific secreted inhibitor Dkk-1 in the intestine (Kuhnert et al., 2004).  
The molecular description of morphogenetic pathways in the intestine received a 
great impulse by studies aimed at defining the genetic background of familial 
syndromes associated with a high risk of colorectal carcinoma, such as Familial 
Adenomatous Polyposis (FAP), Juvenile Polyposis Syndrome and Cowden 
Syndrome. FAP results in the formation of multiple bowel adenomas in the second 
and third decades of life, which almost inevitably progress to colon carcinoma if 
patients are not subjected to prophylactic colectomy (Lynch et al., 2003). In FAP, 
approximately 80% of patients display truncating mutations of the APC 
(Adenomatous Polyposis Coli) gene (Gregorieff et al., 2005). 
The complex processes that contribute to intestinal development and are deregulated 
in tumorigenesis involve the contribution of other pathways acting at the stem cell 
level to control colon homeostasis. The Wnt cascade interplays with the Notch 
pathway to maintain undifferentiated, proliferative cells in normal crypts and 
adenomas (van Es et al., 2005). Another way through which Wnt proteins regulate 
intestinal cell proliferation is by promoting the expression of B subclass ephrins and 
their tyrosine kinase receptors. The transition from adenoma to colon carcinoma is 
associated with loss of ephrin-B receptor expression, and EphB receptors have been 
recently shown to coordinate migration and proliferation in the intestinal stem cell 
niche (Holmberg et al., 2006). The study of Juvenile Polyposis Syndrome (JPS) has 
disclosed another crucial link between molecular genetics and developmental 
biology, revealing the importance of the SMAD/BMP (Bone Morphogenetic Protein) 
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pathway in shaping intestinal architecture. JPS is a condition that predisposes to 
hamartomatous gastrointestinal polyp formation, which can turn into malignant 
lesions in approximately 20% of cases (Haramis et al, 2004). JPS is due to germline 
mutations in the SMAD4 gene in 15-20% of cases, and to mutations in the gene 
encoding bone morphogenic protein receptor 1A (BMPR1A) in 25-40% of cases. 
Bone morphogenetic protein family ligands are expressed by the villus mesenchyme 
while epithelial cells display nuclear phosphorylated SMADs, implying these cells as 
terminal recipients of the signal. By ectopic expression of Noggin, a negative 
modulator of BMP signalling, it is possible to direct the unregulated formation of 
new crypts in the intestine, leading to lesions reminiscent of the hamartomatous 
polyps seen in JPS. This has led to the definition of  ―landscaper‖ function for BMPs 
in the intestine (Fearon et al., 1990)  and highlights the concept that alterations in 
intestinal stem cell microenvironment might be as influential as cell-intrinsic events 
in normal development and tumorigenicity. 
 
 
 
Figure 6.  The Wnt canonical pathway. (Left) In the absence of Wnt stimulation, β-catenin levels 
are kept at a minimum through the destruction complex composed of APC, Axin, GSK3β, and CKI. In 
the nucleus, Tcf factors associate with transcriptional repressors to block target gene activation. 
(Right) In the presence of Wnt stimulation, the destruction complex is destabilized, and β-catenin 
accumulates in the nucleus to activate transcription of Tcf target genes (Gregorieff et al., 2005).  
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3.3  Colorectal carcinogenesis  
 
By a molecular point of view, colorectal carcinoma is one of the best-characterized 
cancer, mainly due to the studies performed on hereditary cases, which account for 
about 15% of colorectal carcinomas, that have significantly contributed to the 
understanding of many biological aspects of this neoplasm. The observation that the 
accumulation of mutations involving oncogenes and tumor suppressor genes follows 
the progression of the disease along the adenoma–carcinoma sequence induced 
Fearon and Vogelstein to formulate in the 1990s the ―adenoma–carcinoma model‖ in 
which the neoplastic process, initiated by APC or β-catenin mutations and tumor 
progression, results from 
the sequential mutation of other genes, such as K-Ras and p53, in the context of a 
growing genomic instability (Fig. 7) (Fearon et al., 1990). This model has been 
further refined and the studies performed on relatively rare inherited cases led to the 
identification of genetic alterations that play a major role in the development of 
sporadic CRC (Ricci-Vitiani et al., 2009). 
Studies on FAP and Hereditary non-polyposis colon cancer syndrome (HNPCC, also 
known as the Lynch syndrome) allowed the identification of two alternative pathogenic 
mechanisms for colon tumorigenesis. Work on FAP identified the "gatekeeper" tumour 
suppressor gene APC as the initial mutation involved in the adenoma-carcinoma 
progression. The early occurrence of APC mutations during colorectal tumorigenesis 
was confirmed by the sequence analysis of 41 colorectal tumors, revealing that most 
adenomas (63%) and carcinomas (60%) contained a mutated APC gene (Powell et al., 
1992). Moreover, other studies indicated that more than 80% of tumors had at least one 
mutation in the APC gene, of which more than 60% had 2 mutations (Miyoshi et al, 
1992). These observations strongly suggest that somatic mutations of the APC gene are 
associated with the development of the great majority of colorectal tumors (Nathke et al., 
2004). APC mutations typically affect the central domain of the protein containing the 
binding site for β-catenin and, consequently, determine the increase of nuclear β-catenin 
and the transcriptional activation of specific target genes, such as the oncogene c-myc 
(Albuquerque et al., 2002; Sansom et al., 2007). Furthermore, approximately 10% of 
colorectal cancers carry activating mutations in the highly conserved serine/threonine 
residues of β-catenin, which are required for recognition and degradation of the protein 
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(Morin et al, 1997). Hereditary non-polyposis colon cancer syndrome is the most 
common form of hereditary CRC characterized by the absence of prior polyp formation 
(Lynch  et al., 1996). 90% of HNPCC patients carry mutations in the ―caretaker‖ 
mismatch repair genes, hMSH2 and MLH1 (Bronner et al., 1994; Leach et al., 1993). 
Consequent inactivation of the mismatch repair system leads to the instability of 
microsatellites, genomic region characterized by multiple repeats of short DNA 
sequences or single nucleotides, which represents the hallmark of tumors in HNPCC. 
The microsatellite instability typical of HNPCC creates a favorable state for 
accumulating mutations in genes that control cell survival, proliferation and self-
renewal, likely fostering the generation of colon carcinomas. Not surprisingly, colorectal 
tumors with mismatch repair deficiency have been shown to bear an excess of frameshift 
mutations in the ―gatekeeper‖ gene APC (Huang et al., 1996). However, it has been 
hypothesized that genomic instability alone is not sufficient for colon cancer 
development, but has to be combined to the selection of genetic alterations through the 
clonal expansion of an aberrant stem cell population. Taken together, the studies 
performed on FAP and HNPCC patients demonstrate the importance of both 
―gatekeeper‖ and ―caretaker‖ gene function. FAP results from an increased rate of tumor 
initiation due to abrogation of the gatekeeper function of APC. In contrast, the mismatch 
repair defect in HNPCC results in an enhanced rate of mutation that greatly accelerates 
tumor initiation. HNPCC and FAP patients both develop cancer at a median age of 42 
years, suggesting that both tumor initiation and tumor progression are rate limiting for 
colon cancer formation. 
 
 
Figure 7. Adenoma–carcinoma sequence model. CIN, chromosomal instability; MMR, mismatch 
repair (Walther et al., 2009).  
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3.4  Colon cancer therapy 
 
The prognosis of colorectal cancer is principally based on the stage of the disease at 
presentation and there is a significantly better survival outcome when detected in 
earlier stages. Adenomas and early cancers are often asymptomatic but potentially 
curable if found and removed as compared to symptomatic colorectal cancer that is 
more likely to be advanced in stage. Screening asymptomatic men and women over 
the age of 50 years for colorectal neoplasia has shown to detect cancers at an earlier 
stage compared to those not screened (Hardcastle et al. 1996; Kronborg et al. 1996; 
Mandel et al. 1993). A number of screening methods are now in use and under 
clinical evaluation, such as fecal occult blood test (FOBT), flexible sigmoidoscopy,  
colonoscopy,  computed tomographic colonography or virtual colonoscopy.  
The only curative strategy in the treatment of colorectal cancer is complete surgical 
resection.  Surgical techniques and survival after surgery have improved over the 
past 15 years.  
Surgery with wide resection margins is the only therapy needed for stage I and II 
disease, although some stage II patients receive chemotherapy (Boland et al. 2000). 
For stage III disease, adjuvant 5-FU-leucovorin or FOLFOX (5-FU, leucovorin, and 
oxaliplatin) for 6 months is standard and has been shown to improve survival 
(Goldberg et al. 2004; de Gramont et al. 2000; Moertel et al. 1995; Moertel et al. 
1990; Laurie et al. 1989; Petrelli et al. 1989). For stage IV, surgery may be curative 
in highly selected patients with resectable bowel disease and resectable isolated 
hepatic or pulmonary metastases. In many patients with stage IV disease, surgery is 
often palliative to prevent bowel obstruction. Chemotherapy is offered but may not 
improve overall survival. Palliative chemotherapy regimens for stage IV colon 
cancer include 5-FU-leucovorin, FOLFOX, FOLFIRI (folic acid/5-FU/irinotecan), 
IFL (irinotecan/5-FU/leucovorin), although IFL is no longer used due to toxicity 
(Goldberg et al. 2004; de Gramont et al. 2000; Douillard et al. 2000; Saltz et al. 
2000; Petrelli et al. 1989). Specific growth factor inhibitors, such as bevacizumab 
and cetuximab added to the 5-FU-based regimens improve tumor shrinkage and 
increase months to the survival of stage IV patients (Jonker et al. 2007; Hurwitz et al. 
2004).  
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It is important to note that systemic therapeutic progress have improved survival of 
patients with metastatic colorectal cancer. Before the 1960s, patients with untreated 
metastatic colorectal cancer had a median survival of 4-6 months. With the 
introduction of 5-FU treatment, patient survival was extended to 11–12 months, and 
5-FU continues to form the core for colorectal cancer therapy (Boland et al. 2000; 
Moertel et al. 1995; Moertel et al. 1990; Laurie et al. 1989). In the 1980s, 
biomodulators such as leucovorin were added to 5-FU, improving the survival by an 
additional 2–4 months (Petrelli et al. 1989). Irinotecan and later oxaliplatin were 
added to 5-FU as second-line treatments, and later were approved as first-line 
therapies for metastatic colorectal cancer, further improving overall survival to 15-17 
months after diagnosis (Goldberg et al. 2004; de Gramont et al. 2000; Douillard et al. 
2000; Saltz et al. 2000). Biological therapies such as cetuximab and bevacizumab 
bring average survival lengths close to 20 months after diagnosis, quadrupling the 
survival times from those observed three decades ago. 
 
Systemic chemotherapeutic agents 
 
5-Fluorouracil:  
5-FU is a fluoropyrimidine that is incorporated into RNA (mRNA, rRNA, and 
tRNA), and is an inhibitor of thymidylate synthase (which catalyzes the rate limiting 
conversion of dUMP to dTMP) to inhibit DNA synthesis (Parker and Cheng, 1990). 
5-FU is typically administered with the biomodulator leucovorin, a reduced form of 
folate that stabilizes the binding between 5-FU and thymidylate synthase (Petrelli et 
al. 1989). It can be given as active intravenous or pro-drug oral forms (capecitabine). 
Deficiency of dihydropyrimidine dehydrogenase (DPD), the exclusive enzymatic 
step for catabolism and deactivation of fluoropyrimidines, can lead to severe 
toxicities with 5-FU. In vitro analysis revealed that 5-FU selectively killed colon 
cancer cells with intact DNA MMR (mismatch repair), while cells without intact 
DNA MMR were 28-fold more resistant (Carethers et al. 1999). 5-FU-resistant cells 
in which DNA MMR was restored became sensitive to 5-FU, similar to other MMR-
proficient cells (Arnold et al. 2003). 
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Irinotecan 
Irinotecan, also known as CPT-11, inhibits topoisomerase I, an enzyme involved in 
the uncoiling of DNA prior to transcription and DNA replication. As a result of the 
uncoiling, topoisomerase I causes single-strand DNA breaks which are transient and 
easily repaired. Irinotecan, by blocking topoisomerase I, stabilizes the breaks within 
DNA, causing DNA fragmentation and ultimately cell death (Klein et al. 2002; 
Douillard et al. 2000; Saltz et al. 2000). Irinotecan is metabolized by hepatic 
carboxylesterases to its active compound, SN-38, and is inactivated through uridine 
diphosphate glucuronosyltransferase 1A1 (UGT1A1) (Klein et al. 2002). 
 
Oxaliplatin 
Oxaliplatin is a platinum derivative, and unlike its cousins cisplatin and carboplatin, 
has synergistic activity with 5-FU in treating colorectal cancer (Goldberg et al. 2004; 
de Gramont et al. 2000). Oxaliplatin forms bulky DNA adducts, and ultimately 
induces cell death, but may also down regulate thymidylate synthase, possibly 
potentiating the efficacy of 5-FU (Raymond et al. 2002; Boland et al. 2000). 
Oxaliplatin as single agent has limited efficacy, and is most efficacious clinically 
when combined with 5-FU-leucovorin in the FOLFOX regimen for patients with 
advanced colorectal cancer (Goldberg et al. 2004; de Gramont et al. 2000). 
 
Targeted biologic therapies for colorectal cancer 
Targeted therapies hold the promise of interrupting key cell pathways that are 
essential for the growth of the tumor, and involved in the cancer cell survival and 
metastasis. Some of these targeted 
therapies are antibodies that can inhibit a receptor, and some are small molecules – 
termed biologic therapy. Given their specific targeted nature, side effects might be 
less than general systemic chemotherapies. 
 
 
Bevacizumab  
Bevacizumab is a humanized monoclonal antibody directed against VEGF, a soluble 
protein involved in angiogenesis process (Ferrara et al. 2003). Bevacizumab alone as 
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monotherapy is ineffective; it has been shown to increase survival in patients with 
metastatic colorectal cancer  when used with the IFL regimen (Hurwitz et al. 2004). 
 
Cetuximab  
Cetuximab is a monoclonal chimeric human/mouse IgG1 antibody directed against 
the extracellular domain of the EGFR, part of the ErbB family of receptors (EGFR is 
also known as ErbB1). EGFR is normally present on epithelium, but is 
overexpressed in some colorectal cancers and associated  with a poorer prognosis. 
EGFR normally enhances pathways involved in cell growth and proliferation; thus 
inhibition of overexpressed EGFR should slow proliferation of cancer cells. 
Activating mutations in KRAS, downstream of EGFR, has been associated with 
resistance to cetuximab therapy, and portends a poorer survival (Lièvre et al. 2008). 
 
Panitumumab  
Panitumumab, like cetuximab, is a monoclonal antibody directed against the 
extracellular domain of EGFR. However, panitumumab is a fully humanized IgG2 
antibody, which may confer a smaller risk for infusion reactions over cetuximab. 
Colorectal cancer patients refractory to therapy had decreased tumor progression 
with panitumumab, and there was improved progression free survival when 
panitumumab was combined with FOLFIRI (Berlin et al. 2007; Van cutsem et al. 
2007). Similar to cetuximab, efficacy is best with wild type KRAS patients, as those 
with mutant KRAS are resistant to therapy and have a poorer survival (Amado et al. 
2008).  
 
Gefitinib  
Gefitinib is a small molecule that targets and inhibits intracellular EGFR tyrosine 
kinase activity. Unlike the extracellular portion of EGFR where monoclonal 
antibodies are used to block EGFR activation, gefitinib inhibits the intracellular 
tyrosine kinase catalytic domain of EGFR that activates downstream signaling events 
and effectors pathways. There is evidence that the tyrosine kinase domain may still 
be a useful target in cetuximab-resistant cells, suggesting that tyrosine kinase 
inhibitors may further modulate signaling that is not fully blocked with EGFR 
36 
antibodies (Huang et al. 2004). Gefitinib combined with FOLFOX achieved a 
median overall survival of twelve months in those patients who previously failed 
chemotherapy (Kuo et al. 2005).  
 
Erlotinib  
Erlotinib is a small molecule that competes with ATP for EGFR‘s tyrosine kinase 
domain. This inhibits receptor autophosphorylation and blocks downstream signaling 
from the intracellular portion of EGFR. Erlotinib has some activity as a single agent, 
and trials are underway as phase III studies and in combination with traditional 
chemotherapy regimens (Townsley et al. 2006).  
 
Lapatinib  
Lapatinib is an ATP-competitive small molecule that is a reversible inhibitor of both 
the ErbB1 and ErbB2 (Her2/Neu) tyrosine kinases (Ponz-Sarvise et al. 2007). 
Lapatinib as a single agent showed some benefit in preventing progression of 
colorectal cancer metastasis in patients who progressed with prior therapy.  
 
Sorafenib  
Sorafenib is an oral multi-kinase inhibitor that has activity against Raf kinase (a 
serine-threonine kinase) and tyrosine kinases, including VEGF receptor, platelet 
derived growth factor receptor (PDGFR), c-kit, and c-Ret (Wilhelm et al. 2006). It 
inhibits tumor cell proliferation by targeting the Ras/Raf/extracellular signal 
regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling pathway 
at the level of Raf kinase, a pathway that is often activated in colorectal cancer, and 
exerts its anti-angiogenic effect by targeting the receptor tyrosine kinases VEGF 
receptor 2, VEGF receptor 3, and PDGFR, and their associated signaling cascades 
(Grady and Carethers, 2008; Wilhelm et al. 2006). It is also found to induce 
apoptosis in some human cancer cell lines by down-regulating the levels of 
antiapoptotic protein myeloid cell leukemia sequence 1 (Yu et al. 2005). Single agent 
therapy showed some clinical benefit in patients with advanced colorectal cancer 
(Strumberg et al. 2005).  
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Aim of the work 
 
 
Numerous reports describe the mir-143 and mir-145 expression as diminished in 
cells of tumoral origin with respect to normal counterparts in colon epithelia and in 
cell lines, and it has been demonstrated that these microRNA can function as 
oncosuppressors, by targeting a number of transcripts that may promote cell 
proliferation, such as the KRAS mRNA, targeted by mir-143 (Chen et al., 2009).  
The genes for mir-143 and mir-145 are located in a 3kb segment on chromosome 5 
and frequently display a coregulated expression profile, suggesting that they are 
transcribed in the same polycystron. Despite accumulating evidence on concomitant 
mir-143 and mir-145 downregulation in colon cancer, their function as players in a 
coordinated scheme of target gene regulation has seldom been studied. It has been 
shown that mir-143 and mir-145 cooperate in promoting smooth muscle cell 
differentiation while mir-145 antagonizes embryonic stem cell  self-renewal (Cordes 
et al., 2009; Xu et al, 2009).  
The antiproliferative effect of mir-143 and mir-145 though documented, has not been 
thoroughly investigated in an integrated framework of common targets and unique 
targets in common or complementary pathways. For example in colorectal cancer 
(CRC), the effect of mir-143 has been implicated in KRAS downmodulation, c-myc 
and IRS-1 might mediate the antiproliferative effect of mir-145 (Sachdeva et al., 
2009; Shi et al., 2007) while IGF-1R, another target of mir-145, does not (La Rocca 
et al., 2009). These evidences have been proved in single overexpression 
experiments, and fit convincingly in the mutational landscape of CRC, with KRAS 
being frequently mutated and c-myc being overexpressed as a result of APC loss of 
function. Other mir-143 targets, such as DNMT3A (Ng et al., 2009) and ERK5 
(Akao et al., 2009), have been proposed to be mediators of an antiproliferative effect, 
but, as for the target genes mentioned above, the relative contribution of any given 
target gene has not been assessed. The levels of mir-143 and mir-145 are decreased 
in multiple tumoral tissues such as lung, breast and lymphoma (Akao et al., 2007), 
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which suggests that a frequent oncogenic lesion, common to these tissues, might be 
implicated. One such lesion is the TP53 gene loss of function, and it has recently 
been demonstrated that p53 pathway activation increases the mir-143 and mir-145 
levels through a posttranscriptional mechanism (Suzuki et al, 2009; Sachdeva et al., 
2009) 
While most reports on mir-143 and mir-145 have considered them as independent 
genes, our study examines the effect of their concomitant re-expression, as we 
speculate that they are co-transcribed and that they have partly overlapping 
functions/target genes. 
First we have investigated the anti-proliferative effect of mir-143 and mir-145 in 
colon cancer cell lines after their overexpression. To this aim we have performed 
functional assays  to investigate the differences in proliferation, migration, anchorage 
independent growth and tumorigenic potential, triggered by miRNA overexpression. 
We have then selected, among the predicted target genes , those transcripts which are 
particularly relevant for their putative role in CRC progression. We found that CD44, 
a membrane glycoprotein that is downregulated at the transcriptional level upon p53 
restoration in breast cancer  is a direct target of mir-143 and mir-145 in CRC cells, 
highlighting the focal impact of p53 in the regulation of CD44 by multiple 
mechanisms (Godar et al., 2008). 
We have identified, as a novel mir-143 and mir-145 target in CRC cells, the KLF5 
gene, which notably is required for KRAS-mediated transformation of normal 
colonic epithelium (Nandan  et al., 2008). Furthermore, we identified as a novel mir-
143 target, the BRAF gene, which is downstream of the already known target KRAS. 
Our results favor the hypothesis that all the target genes we investigated are 
mediators of the mir-143 and mir-145 tumor suppressive capabilities that we 
observed both in vitro and in in vivo xenograft experiments. 
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Materials and methods 
 
 
 
1. Cell Culture 
 
Colorectal cancer cell lines HCT116, SW489 and HT29 from American Type 
Culture Collection (ATCC) were cultivated in the recommended media. In particular,  
HCT116 were grown  in McCoy‘s medium, SW480 were grown in DMEM, HT29 
were grown in RPMI-1640. 
The Human Embryonic Kidney 293T cell line was cultivated in IMDM. They 
contain the SV40 Large T-antigen, that allows for episomal replication of transfected 
plasmids containing the SV40 origin of replication.   
All media were supplemented with 10% (v/v) heat-inactivated FBS, 2 mM L-
glutamine, 100 U/ml of penicillina and 100 µg/ml of  streptomycin (all the products 
are from Gibco).  
 
2. Lentiviral Vectors 
 
For TwG-miR-143-145 generation (TWG-143-5), miR-143-145 precursor DNA  was 
amplified from human genomic DNA. We subcloned the ampliﬁed fragment 
spanning 2347 base pair (chr:5, 148808179-148810515) into the lentiviral vector 
TWEEN under the control of the cytomegalovirus promoter (CMV). TWEEN vector 
carries a EGFP gene under the control of the phosphoglycerate kinase (PGK) 
promoter used to collect transduced positive cells by FACS-sorting. We used the 
following primers for PCR: forward primer 5‘- tgccattgtttgcacaactt -3’ and reverse 
primer 5‘-caagagtacggcagtgctga -3’. 
For the rescue experiments we set out a lentiviral vector-based system for target gene 
expression. We cloned target gene (CDS), lacking of  3‘UTR miR-143 and miR-145 
binding site, in TWEEN-GFP or TWEEN-CFP lentiviral vectors between CMV 
promoter and PGK promoter/GFP or CFP cassette. In particular BRAF, CD44 and 
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KLF5 CDS were cloned in TWEEN-GFP vector, whereas KRAS CDS was cloned in 
TWEEN-CFP vector. All CDS were PCR amplified from human genomic DNA. 
(GeneBank reference are in Reporter assay section). 
For Tet-On inducible system based experiments we used three different lentiviral 
vectors: pLV-rtTA, that consists of rtTA gene under the control of CMV promoter 
and carries a puromycin resistance gene; pLV-tTR consists of a tTR gene under the 
control of thymidine kinase (TK) promoter and carries a neomycin resistance gene; 
pLTR (Lentiviral-Tet-inducible-RFP) or pLTR-143-5 (Lentiviral-Tet-inducible-RFP-
miRs) act as responders to rtTA by inserting, in a lentiviral backbone, a tetracycline 
response element (TRE) upstream of a minimal promoter driving the transcription of 
RFP or RFP/mir-143-5 respectively. TRE consists of seven repeats of tet operator 
(tetO). pLTR-143-5 contains the same genomic region used in TWG-143-5, cloned 
in the 3‘ untranslated (UTR) region of RFP. 
 
3. Lentiviral Infections 
 
Lentiviral particles were produced by calcium phosphate transfection protocol in 
293T packaging cell line. The day before transfection 293T cells were plated at 
density of 2 x 10
6
 cells in a T75 cell culture flask. Cells were transfected with 20 µg 
of lentiviral vector, 13 µg of packaging vector (pPAX) and 7 µg of vescicular 
stomatitis virus protein G vector (pMD2G). CaCl2 (125 mM) and HBS (2XHBS: 
NaCl 280 mM, KCl 10 mM, Na2HPO4 1.5 mM, D(+)glucosio 12 mM, HEPES 50 
mM, pH 7.1) were included in transfection mix to promote calcium phosphate/DNA  
precipitates formation. 24 hours post-transfection culture medium, full of calcium 
phosphate precipitates, was replaced with fresh growth medium. 48 hours post-
transfection, viral supernatant were filtered with 0.45 µm filter and used for the 
following cell lines infection.  
For lentivirus infection colon cancer cell lines were plated in a 6-well culture plate at 
80% of confluence. The day of infection the cells growth medium was replaced with 
2 ml of filtered viral supernatant. Polybrene (4 μg/ml) was used to improve infection 
efficiency. Cell plates were first centrifuged for 45 min at 1800 RPM at 37 
0
C and 
then were incubated for 75‘ at 37 0C. At the end of the infection, the cells  were 
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washed extensively and maintained in usual growth medium. The transduction 
efficiency was evaluated by cytofluorimetric  analysis. 
Colon cancer cell lines transduced with TwG or TwG-mir-143-145 lentiviral 
expression vectors were flow sorted after infection for GFP expression and than used 
for proliferation and in vivo assay. 
In Tet-on inducible based system, SW480 colon cancer cell lines were infected with 
pLV-rtTA and pLV-tTR lentiviral expression vectors and positive cells were selected 
by antibiotic resistance to puromycin and neomycin, respectively.  Successively cells 
were transduced  with pLTR or pLTR-mir-143-145, were induced with the 
tetracycline analog doxycycline and, after two days, RFP-positive cells were flow-
sorted and used for functional assay and target analysis. 
Cells were sorted by BD FACSAria cell sorter according to instructions from facility 
instrument technicians. 
 
4. Flow cytometry  
 
CRC transduced with lentiviral expression vectors (TW or TW-143-5) and lentiviral 
inducible vectors (pLTR or pLTR-143-5) were stained with specific antibody FITC-
conjugated anti-CD44 (RD System) and PE-conjugated anti-ErbB3 (RD System), 
used 1:20 in according to manufacture protocol.  
Xenograft TWG or TWG-143-5 tumor cells were stained with specific antibody PE-
conjugated anti-HLA, used 1:20 (DakoCytomation).  
In rescue assay, SW480 cell lines transduced with pLTR or pLTR-143-5, and TWG-
CD44 were analyzed by staining with APC-conjugated anti-CD44 used 1:20 (RD 
System). 
FITC, PE or APC conjugated anti-human IgG antibody were used 1:20 as control 
(BD Bioscence). 
Cells were washed with PBS 
 
and incubated with control or specific antibodies.  
After 1 hour of incubation, labeled cells were washed twice with PBS and
 
fluorescence intensity was evaluated by FACScanto (Becton Dickinson,
 
San Jose, 
CA). 
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5. RNA isolation and Real- Time PCR analysis 
 
Total RNA was extracted with TriZol method at different time point (for a period of 
two weeks post-sorting). Fifty nanograms of RNA were reverse transcribed with M-
MLV reverse transcriptase (Invitrogen) or TaqMan  reverse transcriptase (Applied 
Biosystems) and cDNA was diluted 1:10 in  the PCR reactions. Housekeeping gene 
and target gene reverse transcription was performed using oligo-dT primers 
(Invitrogen), while  miRNA  specific  looped-primers were used for  miR-143  and  
miR-145  reactions.  
TaqMan microRNA  assays  (Applied  Biosystems)  for miR-143  and miR-145  
were  used  for  PCR amplification. Normalization was performed using snRNA U6 
as reference (RNU6B TaqMan  microRNA  assay,  Applied  Biosystems).   
Target genes  of  retrotranscribed  RNA  were  amplified  using  0.5 pmol of each 
specific primer by SYBR Green real time PCR (SYBR Green PCR Master Mix, 
Applied Biosystems). Normalization was performed using Peptidil Prolil Isomerase 
(PPIA) as reference. 
Calibration was performed using cDNA samples from colon cancer cell line infected 
with control vector (pLTR or TWG). Values are expressed in terms of 2
- ΔΔCT
 where  
ΔΔCT =  ΔCTsample -  ΔCTcalibrator , ΔCT  was the difference in threshold cycles 
between the miR or target gene and snRNAU6 or PPIA amplicons, and CT was a 
parameter given by ABI PRISM 7900 Sequence Detector software according 
manufacturer‘s instructions (Applied Biosystems). 
Each experiment was performed in duplicate for three times. 
 
RT-PCR primer sequences for gene target are:  
Primer name Primer forward Primer reverse 
K-Ras  cccaggtgcgggagagaggc ctacgccaccagctccaact 
B-Raf tcccatcagtttgaacagttgtct ctgtatggatttttatcttgcattctg 
KLF5 tggagaaacgacgcatcca gtcgcagccttcccaggta 
CD44 gctctgagcatcggatttgag tttgctgcacagatggagtt 
ErB3 gaggaagaggatgtcaacggtta gaactgagacccactgaagaaagg 
PPIA ggccgcgtctcctttga agtgctcagagcacgaaaatttt 
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6. MicroRNA target prediction 
 
We used TargetScan (http://genes.mit.edu/targetscan), miRanda 
(http://www.microrna.org), and PicTar (http://pictar.bio.nyu.edu) for mir-143 and 
mir-145 target prediction. The targets  were confirmed by BLAST alignment with the 
corresponding NCBI DNA data base for homologies between miRs and their target. 
Moreover, putative target were selected for their involvement in colon cancer 
pathogenesis.   
 
7. Western Blots 
 
Cells pellets were collected at different time points (for a period of two weeks post-
sorting).  Protein  extracts  were  prepared  by  resuspending  cell  pellets  in  RIPA  
buffer  (20  mM Tris/HCl pH 7.2, 200 mM NaCl, 1% NP40) with Protease and 
Phosphatase Inhibitor Cocktails I and II (Sigma-Aldrich). Samples were resolved in 
SDS-PAGE gels (NuPage 4-12% bis-tris Gel invitrogen), and proteins were loaded 
in equal amounts after measurement with Bradford assay (Biorad). Proteins were 
transferred to nitrocellulose and samples were analyzed by standard  immunoblot  
procedure. After blocking, the membrane was incubated overnight at 4°C with the 
following primary antibody diluted in TBS/0.2% Tween  with 1% BSA: anti-KRas 
(1:300) , anti-BRaf (1:300), anti-BTEB2 (KLF5) (1:1000). All primary antibodies are 
from Santa Cruz Biotechnology. Anti-β-actin monoclonal  antibody  was  used  as  
loading  control (Oncogene Research Products, San  Diego, CA). 
Then, the membrane was incubated with a horseradish peroxidase-conjugated 
donkey anti-rabbit or anti-mouse immunoglobulin antibody (1:4000) in 
TBS/0.2%Tween  with 5% milk for 1 hour at RT.  
The specific protein-antibody reaction was detected by the Super signal West Pico 
Chemioluminescent Substrate (Pierce).  
The quantitation of protein expression was determined after normalization to β-actin, 
by measuring the optical density of respective band blots using the Quantity One 
software (Biorad). 
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8. Reporter assay 
 
The potential binding sites of miR-143 and miR-145 on 3‘UTR of gene target 
(except b-Raf where target region is in the coding sequence) were cloned 
immediately downstream of the stop codon of the Renilla coding sequence into 
multiclonal site (MSC) of a dual-luciferase vector psiCHEK-2 (Promega).  
For RAS, two miR-143 3‘UTR target regions of about 200 bp were amplified from 
human genomic DNA, corresponding to residues 2222-2436 (143Ta) and 4365-4582 
(143Tb) of Genbank Acc N° NM_004985.3. 
For Raf, one miR-143 coding sequence (CDS) target region of about 100 bp 
fragment was amplified (residues 370-552 of N° NM_004333.4). 
For KLF5, one miR-143-145 3‘UTR target region, of 761 bp fragment was amplified 
(residues 1429-2189 of N° NM_001730.3). 
For CD44, one miR-143 and one miR-145 3‘UTR target region, of about 200 bp was 
amplified (residues 2258-2438 and 3283-3515 of N° NM_001001391.1). 
First, PCR fragments were cloned in pCRII-topo vector (TOPO TA Cloning Kit Dual 
Promoter, Invitrogen), then were transferred in psiCHEK-2 between XhoI and SpeI 
restriction site. 
 
Primer sequence used are: 
Primer name Primer forward Primer reverse 
KLF5T143/145-wt tggagaaacgacgcatcca cccacacatttgttcaatgg 
RasT143a-wt gactcgagatggcatggtga cccgatatcgtgctgagcttgaca 
RasT143b-wt tcggagctcttgtggggcatgtt gctttaaaggtaactgctgggttc 
CD44T143-wt gccctcgagcactgtctgggtccctac cgcactagtcaggatggaaaacctttgga 
CD44T145-wt ccttacgtaccacttcaccccacaatctt gccactcgagtggcttgttgcttttc 
RafT143-wt gggctcgagactgatttttct ctgtcgactgtttgttgggca 
 
For mutant derivative constructs double strand oligos were generated by annealing 
sense and antisense mutated strands, and further ligated into psiCHEK2 digested 
with XhoI and SpeI. Mutation was performed in the ‗seed‘ sequence where 
nucleotide 2-8 were substituted with restriction enzyme site.  
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Oligos sequence are: 
Name XhoI – 3’UTR oligo (s) / SpeI – 3’UTR oligo (as) 
KLF5 
T143-mut 
tcgataatgtatatggctttactcaagcagatcgctagccatgacaggcagccacgtctcaacatgggt 
ctagacccatgttgagacgtggctgcctgtcatggctagcgatctgcttgagtaaagccatatacatta 
KLF5 
T145-mut 
tcgaaacaaacaaaagcaagaaaaccacaactaatgtacaaaatgtatattttgtatatttgagaaaac 
ctaggttttctcaaatatacaaaatatacattttgtacattagttgtggttttcttgcttttgtttgtt 
Ras 
T143a-mut 
tcgattactatccatttcttcatgttaaaagaaggctagccaaactcttagttttttttttttacaact 
ctagagttgtaaaaaaaaaaaactaagagtttggctagccttcttttaacatgaagaaatggatagtaa 
Ras 
T143b-mut 
tcgatgttaagttacagtttgcacaagtgatatccatttgtattccattgattttttt 
ctagaaaaaaatcaatggaatacaaatggatatcacttgtgcaaactgtaacttaaca 
CD44 
T143-mut 
tcgaaatggtaaggagactcttctaagtctatgcatcagagaccctgagttcccactcagacc 
ctagggtctgagtgggaactcagggtctctgatgcatagacttagaagagtctccttaccatt 
CD44 
T145-mut 
tcgattctttttattttcttttcaacttgaaagatctagaacattaggccactatgtgttgttactgcc 
ctagggcagtaacaacacatagtggcctaatgttctagatctttcaagttgaaaagaaaataaaaagaa 
Raf 
T143-mut 
tcgactagcctttcagtgctacctgatatcctttcagtttttcaaaatcc 
ctagggattttgaaaaactgaaaggatatcaggtagcactgaaaggctag 
The underlined nucleotides are Xho- 5‘end and SpeI- 3‘end protruding of the double strand oligo. Red 
nucleotides are ‗seed‘ mutated site.   
 
For transfection experiments, CRC cell lines were seeded in 24-well plate and then 
transfected with Lipofectamine 2000 according to manufacturer‘s instructions 
(Invitrogen). 
CRC cell lines were transfected with 0.2 g of renilla-luciferase vectors (empty 
psiCHEK2 and psiCHEK2-target 3‘UTR/CDS wt or mutant) and 1.8 g of miR-143-
145 expression vector (empty Tw or Tw143-145). Luciferase activities was detected 
48h after transfection by using Dual-Luciferase reporter assay (Promega).  
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Transfection efficiencies were normalized by calculating the ratio renilla/firefly. For 
each 3‘UTR target region the relative renilla activities was calculated by dividing the 
values obtained in wt vector by those of mutated. Each experiment was performed in 
duplicate and replicated three times. 
 
9. Proliferation assay 
 
Transduced colon cancer cell lines (SW480, HCT116, HT29) were seeded at a 
density of 2000 cells per well in 96-well plates. Rates of proliferation were 
determined using Cell Titer Blue assay (Promega) after 0-, 3-, 4-, 5-, 6- days. 
Proliferation was measured by evaluating of 490nm absorbance, which is directly 
proportional to the number of living cells. Each experiment was done in quintuplicate 
and replicated three time. 
 
10. Soft agar colony formation assay 
 
Assays of colony formation in soft agar were done using standard protocols. Briefly, 
transduced CRC  cell lines were seeded at same density (5 × 10
2
 cells per well). Cells 
were suspended in 0.35% Agar Noble and were plated onto a layer of 0.7% Agar 
Noble in cell medium in 24-well tissue culture plates (Corning). The agar containing 
cells was allowed to solidify overnight at 37°C in 5% CO2 humidified atmosphere. 
Colony formation was determined after two weeks by staining with 0,5ml of 0,005% 
Crystal Violet for 1 hour. Visible colonies were counted with the aid of a 
microscope. 
 
11. In vitro cell migration assay 
 
The motility of transduced CRC  was evaluated in 24-well transwell chambers 
(Costar), as directed by the manufacturer. Briefly, the upper and lower culture 
compartments of each well are separated by polycarbonate membranes (8 μm pore 
size). The lower chambers of the 24-well plate were filled with 500 μL of cell 
medium; 2 × 10
3
 cells in 200 μL of the same medium was placed into the upper 
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compartment of wells. The transwell chambers were incubated at 37°C in 5% CO2 
humidified atmosphere for 48 h. The cells that had not invaded were removed from 
the upper face of the filters using cotton swabs. The cells that had invaded to the 
lower surface of the filters were fixed and stained with coomassie blue, and 
quantified by counting the numbers of cells that penetrated the membrane in five 
microscopic fields (at ×100 magnification) per filter. The experiment was repeated 
twice. 
 
12. In vivo assay 
 
Six-eight week old male NOD-SCID mice (Charles River Laboratoty, Wilmington, 
MA) were used for examining the tumorigenicity of colon cancer cell lines 
transduced with TWG or TWG-143-5 lentiviral vectors. A total of 200 µl of cell 
suspension in Matrigel (1:1, vol/vol) was subcutaneously injected into the dorsal 
surface of mice (cells transduced with TWG vector on the right and cell transduced 
with TWG-143-5 on the left of the same mouse). The number of cells injected was 2 
x 10
5 
and three mice were inoculated for each cell line. Tumor size was monitored 
for 7 weeks by measuring the length (L) and width (W) with caliper. Volumes were 
calculated by using the following formula: (L x W
2
) x 0,52. At the end of the 
experiment mice were sacrificed and mir-143 and mir-145 expression levels were 
verified by RT-PCR and FACS analysis. 
 
13. Cytotoxicity assay 
 
SW480 colon cancer cell lines transduced with LTR and LTR-143-5 vectors were 
flow sorted and plated at density of 2000 cell per well in a 96-well plate. The day 
after seeding cells were treated with three different concentration of 5-Fluorouracil 
(25, 50 and 100 uM), Oxaliplatin (5, 10 and 20 uM) and Irinotecan (5, 10 and 20 
uM). Chemotherapeutic agent are Sigma (5-Fluorouracil, Oxaliplatin) and Alexis 
(Irinotecan). After 72 hours of treatment cell viability was assessed using Cell Titer 
Glo assay (Promega).  
Each experiment was done in quintuplicate and replicated three times. 
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Results 
 
 
 
We have started our work by investigating the anti-proliferative effect of mir-143 
and mir-145 overexpression in colon cancer cell lines. We  first set out a lentiviral 
vector-based system for mir-143 and mir-145 expression. A genomic region 
harboring the two miRNAs genes was cloned in a lentiviral vector TWG between a 
CMV promoter and a PGK promoter/GFP cassette, yielding TWG-143-5 (Fig. 8a). 
We checked the functionality of TWG-143-5 by comparing the mir-143 and mir-145 
expression levels in colon cancer GFP-positive cell lines (Hct116, HT29, Sw480) 
infected with TWG and with TWG-143-5 respectively. Relative quantification by 
Real time PCR revealed that the mir-143 and mir-145 levels were increased by one 
and two orders of magnitude, respectively (Fig. 8b). This is coherent with mir-143 
being the most abundant transcript in every cell type analyzed on a quantitative basis 
so that, increasing both microRNAs by the same amount, the relative increase is 
higher for the less abundant transcript.  
Fig. 8b shows that high levels of mir-143 and mir-145 expression are achieved at late 
time points. The range of upregulation was comparable to the difference observed in 
mir-143 and mir-145 between normal and tumoral tissue from the intestine (Bandres 
et al., 2006). Hence, we proceeded to the analysis of tumoral behavior in CRC cells 
where these microRNAs have been restored to normal levels.  
We analyzed the growth kinetics in HCT116, SW480 and HT29 cells transduced 
either with TWG or with TWG-143-5. Cells were flow sorted for GFP expression 
and then plated (2000 cells/well) in quadruplicate in a 96 well plate. Growth kinetics 
were analyzed over  a period of one week, and in all cell lines the population 
transduced with TWG-143-5 displayed a limited degree of retarded growth (Fig. 8c). 
We also observed that, upon prolonged culturing (more than two week), the two 
populations became indistinguishable in terms of growth properties. When we 
analyzed the levels of mir-143 and mir-145 after the occurrence of this phenomenon, 
we could not detect significant differences in proliferation assays, indicating that the 
counter-selection operated by these microRNAs favored the emergence of cells that, 
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by an unknown mechanism, have restored the levels of mir-143 and mir-145 to those 
typical of a tumor condition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. a) Schematic description of TWG and TWG-143-5 vectors. b) mir-143 and 
mir-145 relative expression levels in Hct116 cells transduced with TWG and TWG-
143-5 vectors, data are normalized to control vector (empty TWG). c) Growth 
kinetics in Hct116 cells transduced with TWG and TWG-143-5 vectors. We show 
only data for Hct116 but results are similar in the other cell lines mentioned. 
b)
c)
a)
TWG
TWG 143-5
5’ LTR CMV EGFPPGK 3’LTR
5’ LTR CMV EGFPPGK 3’LTRpri miR143-5
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In order to observe the effect of mir-143 and mir-145 shortly after their enforced 
expression, we decided to set up an inducible system for microRNAs expression.  
We used the Tet-On gene expression system technology (Gossen et al, 1995) by 
engineering colon cancer cell lines with three different lentivirus expression vectors: 
pLV-rtTA, pLV-tTR and pLTR-143-5 (or pLTR related control).  
rtTA (reverse tetracycline-controlled transactivator) is a fusion protein consisting of 
rTetR (the reverse mutant of TetR) and VP16 activation domain (from herpes 
simplex virus). rtTA binds specifically to tetracycline responsive element (TRE) and 
activates transcription in the presence of doxycyclin. tTR (tetracycline-controlled 
transcriptional repressor) is a fusion protein consisting of the TetR and KRAB-AB 
domain of Kid-1. It binds specifically to the TRE and suppresses transcription in 
absence of Dox. pLV-tTR is designed to prevent unregulated mir-143 and mir-145 
expression in the Tet-On system.  pLTR-143-5 (or pLTR) is the response plasmid of 
rtTA which expresses RFP/miR143-miR145 (or only RFP) under the control of TRE. 
In pLTR-143-5 the genomic region used in TWG-143-5 was cloned in the 3‘ 
untranslated (UTR) region of RFP (Fig. 9a). In absence of doxycyclin tTR binds 
TRE and miRNAs transcription is repressed. In presence of doxycyclin rtTA binds 
TRE and miRNAs expression is activated. 
First, SW480 colon cancer cell lines were infected with pLV-rtTA and pLV-tTR 
vectors. Positive cells were selected by antibiotics resistance to puromycin and 
neomycin respectively, and than were infected either with pLTR or its derivative 
pLTR-143-5. After infection, cells were induced with the tetracycline analog 
doxycycline and, after two days, RFP-positive cells were flow-sorted and used in 
functional assays.  
For proliferation assay, cells were plated (2000 cells/well) in quadruplicate in a 96 
well plate. Inducible expression of mir-143 and miR-145 had an inhibitory effect on 
the growth properties of Sw480 cell line (Fig. 9b). Overexpression of mir-143 and 
mir-143 were confirmed by Real Time-PCR (Fig. 9c). 
 
 
 
 
 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. a) Schematic description of pLox-rtTA, pLox-tTR, pLTR and pLTR 143-5 
vectors. b) Growth kinetic of Sw480 cell line infected with constructs in a) after 
doxycycline induction. The day of the sorting being day 0. c) Relative miR-143 and 
miR-145 expression level in Sw480 infected with construct in a) after doxycycline 
induction, data are normalized to control vector (empty pLTR).  
a)
b)
c)
pLV-rtTA
pLV-tTR5’ LTR SV40 tTRTK 3’LTRNEO
pLTR5’ LTR RFPTRE 3’LTR
pLTR143-5Pri miR143-55’ LTR RFPTRE 3’LTR
5’ LTR CMV PUROPGK 3’LTRrtTA
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We then examined the migration ability of SW480 cell lines transduced with pLTR 
or pLTR-143-5 expression vector. 2 × 10
3 
cells, obtained as  previous described, 
were plated in a 24-transwell microporous chamber, and incubated for 48h. We 
observed a dramatic reduction in the migration capabilities of the cell population 
overexpressing mir-143 and mir-145, at a high extent which could not be attributed 
merely to a decrease in the proliferation, given the short duration of the assay (Fig. 
10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. a) Sw480 pLTR and pLTR-143-5 cell lines fixed and stained with 
coomassie blue in transwell chambers. b) Graph shows the  number of  migrated 
cells in Sw480 cell line, 48h post-sorting. (* p < 0,05). 
 
The same cells used for the migration assay were used to assess whether reinforced 
expression of mir-143 and mir-145 might influence the ability to grow in an 
anchorage-independent manner. To this aim, 5 × 10
2 
cells were plated in soft agar, 
then, after 16 days, plates were stained with Crystal violet and colonies were counted 
SW480
LTR 143/5LTR
a)
b)
*
53 
(Fig. 11a). The histogram shows a decrease in anchorage independent growth ability 
in SW480 pLTR-143-5 compared to the control vector transduced cells (Fig. 11b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. a) Sw480 pLTR and pLTR-143-5 cell lines in soft agar, after 16 days. b) 
Graph shows the  number of colonies formed in semisolid medium in Sw480 cell 
lines, 16 days post-sorting. (* p < 0,05). 
 
At this point we asked if the restoration of mir-143 and mir-145 expression level 
might influence the sensibility to the most commonly used chemotherapeutic drugs 
for the treatment of colon neoplasia. To this aim, we performed a toxicity assay with 
SW480 LTR and LTR-143-5 cell lines. Sorted cells were plated and treated with 
three different concentrations of 5-fluorouracil, irinotecan and oxaliplatin. The 
results are shown in Fig. 12, where a dramatic increase in the effect of the drug after 
72h of treatment is observed as cell death, indicating that mir-143 and mir-145 do not 
LTR 143/5LTR
SW480
a)
b)
*
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only affect proliferation of CRC cells, but also their survival, opening the possibility 
that they influence a set of genes with pleiotropic properties.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Chemosensitivity of Sw480 cell lines overexpressing mir-143 and mir-
145 compared to control cells after 72 hours of  treatment with the drugs and the 
doses indicated. (** p < 0,01) 
 
Having confirmed that the coordinated expression of the mir-143 and mir-145 
transcripts provokes a decrease in tumorigenic properties of SW480 colon cancer cell 
lines in the standard culture conditions, we endeavored to translate our findings in an 
in vivo model of tumor growth. To this aim, colon cancer cells lines (Hct116, HT29 
and SW480), transduced with either TWG or TWG-143-5, were injected 
subcutaneously in SCID mice, and tumor formation was monitored over seven 
weeks. As shown in Fig. 13a, both cell populations are able to form tumor in vivo, 
but the tumors overexpressing mir-143 and mir-145 display a significant delay in 
their growth, which is possibly due to the time required for the outgrowth of a clone 
that escapes the growth inhibitory effect, as already detected in prolonged in vitro 
culturing. This is further supported by the fact that, once animals are sacrificed and 
**
**
**
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their tumors are evaluated for mir-143 and mir-145 levels (Fig. 13b), the difference 
in levels between those originated from TWG-transduced cells and those originated 
from TWG-143-5 are blunted, despite both populations being GFP-positive (Fig. 
13c). Indeed, oncosuppressor functions are supposed to impart to tumoral cells a 
disadvantage that, depending on its strength, might manifest in a different range of 
phenotypes, from no growth to slightly reduced, but the possibility exists that, 
especially in gene transfer experiments, escape from a critical condition is achieved 
through transgene silencing. 
The above experiments favour the hypothesis that mir-143 and mi-145 loss of 
expression might represent an oncogenic event that, as recently demonstrated, could 
be attributed at least partly to p53 loss of function (Suzuki et al, 2009; Sachdeva et 
al., 2009).  
To understand more deeply the mechanism by which these microRNAs can behave 
as oncosuppressors, we tried to establish whether any of their putative targets might 
represent a crucial function in colon cancer oncogenesis. We identified, among the 
target genes predicted by TargetScan (Lewis et al., 2003), some transcripts which 
were particularly suggestive for the role that they play in colon cancer progression. 
Among these, k-Ras (targeted by mir-143) is activated by mutations in 50% of 
colorectal cancer patients (Arber et al., 2000; Bos et al, 1987), b-Raf (targeted by 
mir-143) is the immediate downstream effector of k-Ras in the mitogen-associated 
protein kinase (MAPK) pathway, Klf5 (targeted by mir-143 and mir-145) is a tissue-
specific transcription factor which mediates the transformation of normal colonic 
epithelium by oncogenic k-Ras (Nandan et al., 2008), ErbB3 (targeted by mir-143 
and mir-145) encodes EGFR3, a receptor of EGF which stimulates the MAPK 
pathway through Ras and is highly expressed in colon cancer cell lines (Wu  et  al., 
2009). Finally, CD44 (targeted by mir-143 and mir-145), is a plasma-membrane 
protein with an important role in cell survival and migration, and is repressed by  
p53. While the effect of mir-143 on k-Ras in colorectal cancer tissues has been 
proposed elsewhere, the remaining targets are novel, with the exception of Klf5 
which was demonstrated to be a target of mir-145 in vascular smooth muscle cells 
(Cheng et al., 2009). Notably, the b-Raf transcript has a target site for mir-143 in its 
coding region, which is neglected by most target prediction engines (Fig. 14).  
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Figure 13. a) Tumor volume in SCID mice inoculated with TW or TW-143-5 HT29 
cell lines. b) Relative mir-143 and mir-145 expression level in tumor xenograft cells 
after seven weeks. Data are normalized to control vectors (empty TW). c) FACS 
analysis of GFP expression in tumor xenograft cells after mice sacrifice.  
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Gene Position Target Site 
KRAS 
1602-1608 
 
5'  ...UCAUGUUAAAAGAAGUCAUCUCA...  (UTR) 
                      |||||||  
3'       CUCGAUGUCACGAAGUAGAGU     (miR-143) 
 
KRAS 
3647-3653 
 
5' ...ACAGUUUGCACAAGU--UCAUCUCA... (UTR) 
               |||     |||||||  
3'        CUCGAUGUCACGAAGUAGAGU    (miR-143) 
 
KLF5 
112-118 
 
5'   ...GAAAACCACAACUAAAACUGGAA... (UTR) 
                       |||||||  
3'      UCCCUAAGGACCCUUUUGACCUG    (miR-145) 
 
KLF5 
238-244 
 
5' ...UUACUCAAGCAGAUC-UCAUCUCA...  (UTR) 
               |||    |||||||  
3'       CUCGAUGUCACGAAGUAGAGU     (miR-143) 
 
CD44 
784-790 
 
5' ...CUUCUA-AGU-CUUCAUCUCA ...    (UTR) 
         ||| ||| ||||||||| 
3'    CUCGAUGUCACGAAGUAGAGU        (miR-143) 
 
CD44 3387-3393 
5' ... UUUUCAACUUGAAAGAAACUGGAC... (UTR) 
                       |||||||  
3'      UCCCUAAGGACCCUUUUGACCUG    (miR-145) 
BRAF 459-465 
5' ... CUUUCAGUGCUACCUUCAUCUCU...   (UTR) 
                      |||||||  
3'       CUCGAUGUCACGAAGUAGAGU     (miR-143) 
 
Figure 14. a) Summary of miR-143 and miR-145 target site in the 3‘UTR/CDS of 
KRAS, KLF5, CD44 and BRAF. The underilined nucleotides (‗seed‘ sequence)  
were mutated in reporter assay costructs. 
 
We therefore analyzed the levels of target proteins at different time points after the 
induction of the transgene in cells transduced both with pLTR/pLTR 143-5 inducible 
vectors system and with TW/TW 143-5 vectors system. The mir-143 and mir-145 
levels reach a maximum at day 4-5 post-sorting, then fluctuating for the remaining 
part of the assayed time. We therefore chose to assay the target protein levels 2 days 
after the attainment of full microRNA induction, in order to allow for protein and 
transcript turnover to be affected by posttranscriptional repression. Results in 
Fig.15a show that Klf5, k-Ras and b-Raf target proteins are significantly diminished 
in cells where mir-143 and mir-145 are induced, althougt to a different extent that 
might arise from differential affinity of the microRNA for the transcript, differential 
transcript/protein half-life or other factors. For CD44 and EGFR3 proteins, we 
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assayed the levels of native, processed membrane proteins as these are more 
informative for the functional consequences. Cells were therefore incubated with the 
appropriate FITC and PE conjugated antibodies, followed by facs analysis. Although 
ErbB3 appeared not affected by mir-143 and mir-145 induction (Fig. 15b), CD44 
was 20% diminished in pLTR-143/5 cells induced with doxycyclin compared to 
pLTR control (Fig. 15c). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. a) k-Ras, b-Raf and Klf5 protein levels revealed by immunoblotting in 
SW480 cell line transduced with pLTR or pLTR-143-5, 10 days post-sorting , β-actin 
is used as loading control. b) CD44 protein levels assayed by immunostaning in 
SW480 cell lines transduced with pLTR or pLTR-143-5, 10 days post-sorting.  c) 
ErbB3 protein levels assayed by immunostaning in SW480 cell lines transduced with 
TW or TW 143-5, 10 days post-sorting. 
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β-actin
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62 kDa
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We then investigated whether the decrease in the target proteins could be attributed 
to the direct action of the overexpressed microRNA on the target transcripts. To do 
this, we first performed the relative quantification of target transcripts in the cell 
lines used for the protein analysis experiments, secondly we created luciferase-based 
reporter constructs bearing part of the target transcript 3‘UTR/CDS after the renilla 
reporter protein stop codon (Fig. 17a).  
Our results show that the mRNA for the target proteins remain unaffected by 
microRNA overexpression, so that the mechanism leading to protein downregulation 
is essentially posttranscriptional in nature (Fig. 16).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Relative expression levels of gene target in SW480 LTR-143-5 
compareded to SW480 pLTR, 10 days post-sorting. 
  
When we performed the reporter gene experiments, we compared the activity of the 
target 3‘UTR/CDS construct with that of a cognate construct bearing a mutation of 
the ―seed‖ sequence, that is, the sequence that base pairs with residues 2-8 of the 
microRNA. We thus obtained the relative strength of inhibition for the 
microRNA/target site pair, showing that all the target sites we found were genuine 
(Fig. 17b). However, for Raf we didn‘t observe any inibition of luminescent signal in 
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miRNA/wt target site pair compared with mutant, probably because the putative mir-
143 binding site is in the CDS of the gene target. Moreover we analyzed two target 
binding site in 3‘UTR of Ras, but only one (143a) seem to be active. 
This data provided the molecular basis for the assumption that mir-143 and mir-145, 
being coregulated and sharing targets and affected pathways, can be considered as 
part of a system of gene repression that integrates in the oncosuppression mechanism 
elicited by p53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. a) Schematic description of the reporter construct used for the validation 
of mir-143 and mir-145 base pair on the target transcripts. The putative 3‘UTR/CDS 
miR-143 and -145 binding site wt and mutated were cloned in MCS (multicloning 
site) b) Relative renilla activities was calculated by dividing the values obtained in 
3‘UTR/CDS binding site wt vector by those of mutated. (* p < 0,05).  
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The subset of target genes we identified is centered in the MAPK activation pathway, 
with the exception of CD44 being at least partly connected with the suppression of 
growth by p53. To ascertain whether decrease in any of these proteins mediates the 
oncosuppressive properties of the mir-143-145 system, we performed proliferation  
and migration assay with the concomitant transduction of lentiviral constructs that 
allow the restoration of single target genes, so as to observe partial or total phenotype 
recovery.  
Target genes lacking mir-143 and mir-145 binding site were cloned in a lentiviral 
vector TW-GFP or TW-CFP between a CMV promoter and a PGK promoter/GFP or 
CFP cassette. First, colon cancer cell lines (Hct 116, Sw480, Ht29) were infected 
with inducible vector based-system (pVL-rtTA, pVL-tTR) and positive cells were 
selected by antibiotic resistance. Next, cells were infected with the lentivirus for 
constitutive expression of the mir-targeted gene (TW-target) and positive cells were 
collected by FACS-sorting. Finally, cells were infected with pLTR or pLTR-143-5 
vector, induced with doxycycline and  after two days RFP-positive cells were flow-
sorted and used for the next assays. 
In functional rescue assays, target gene restoration induced an increase in terms of 
proliferation and migration ability of colon cancer cell lines compared with cells 
were only miR-143 and mir-145 are overexpressed.  Proliferation and migration 
enhancement is comparable to cells infected with pLTR only (Fig 18-19).  
We confirmed k-Ras, b-Raf, Klf5 protein overexpression by immunoblotting and 
CD44 protein overexpression by immunostaning.  Fig 20 shows that target protein 
levels increase when mir-143 and mir-145 are expressed in association with TW-
target vectors compared with cells where miRNAs are overexpressed alone.  
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Figure 18. a) Growth kinetic of Sw480 cell line infected with pLTR, pLTR 143-5 or 
pLTR 143-5/TW-target lentiviral vectors indicated.  b) Graph shows percentage  of 
proliferation SW480 cell line infected with indicated target at 4 day post-sorting. (* p 
< 0.05). 
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Figure 19. a) Migrated SW480 cell line fixed and stained with coomassie blue 48 
hours post-sorting. b) Percentage of migrated cells infected with indicated vectors 48 
hours post- sorting. 
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Figure 20. a) k-Ras, b-Raf and Klf5 protein levels revealed by immunoblotting in 
colon cancer cell lines with or without  TW-target overexpression vectors, 10 days 
after the last sorting. b) CD44 protein levels revealed by FACS analysis in colon 
cancer cell lines with or without  TWG-CD44 overexpression vectors, 10 days after 
the last sorting. 
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However, none of them can, by itself,  allow for the full restoration of the 
proliferation capabilities that are affected by mir-143 and mir-145. We also 
performed double coexpression experiments with Klf5 and k-Ras, as a synergistic 
effect was expected based on previous evidences (Nandan et al., 2008). Proliferation 
was partially restored also in this case (Fig. 21). We cannot exclude that expressing 
the two transgenes over their physiological levels might lead to compensation of b-
Raf and CD44 deficit. When we examined the effect of target restoration on the 
migration capabilities of CRC cells overexpressing mir-143 and mir-145, we could 
observe that restoring RAS expression was sufficient to completely recover the 
ability of CRC cells to migrate, while a weaker effect was seen upon overexpression 
of CD44, BRAF and KLF5. Again, it might be inferred that the weak effect is 
dependent on nonphysiological levels attained through the use of a strong promoter, 
and that a recovery in the proliferation capabilities might slightly affect the readout 
of the migration assay.  
Rescue assay results favor the hypothesis that downmodulation in all target genes is 
responsible for the oncosuppressive properties of mir-143 and -145.  
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Fig 21. a) Growth kinetic of Sw480 cell lines infected with pLTR, pLTR 143-5 or  
pLTR 143-5, TWC-Ras and TWG-klf5 lentiviral vectors. b) Percentage of 
proliferation SW480 cell line in a) at 4 day post-sorting. c) Percentage of SW480 
migrated cells infected with the same vectors as in a) 48 hours post- sorting. 
**
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Discussion 
 
 
 
Deregulation of gene expression is currently one of the most studied molecular 
features of diseased tissue, both for diagnostic and therapeutical purposes. The 
identification of recurrent patterns of differential gene expression in normal and 
diseased tissue has helped to clarify that gene profiles are intertwined with the array 
of mutation that are causative to the genesis of a given pathology. Some of the most 
known oncogenic lesions, for example those leading to loss of function of TP53 or to 
c-Myc overexpression, have been found to entail the differential expression of a 
subset of microRNAs that might be active players in the mechanism of oncogenesis 
or oncosuppression, hence representing a point of therapeutic intervention. To 
distinguish between microRNAs whose downregulation is a mere bystander event to 
the oncogenic lesion, and those which are intrinsic to oncosuppression, functional 
assays can be performed, where their transcript are re-expressed back to normal 
levels.  
Most reports on mir-143 and mir-145 have considered them as independent genes, 
while our study examines the effect of their concomitant re-expression, as we 
speculate that they are co-transcribed and that they have partly overlapping 
functions/target genes. We found that enhanced expression of mir-143 and mir-145 
in CRC cells might lead to oncosuppression by altering the cells‘ ability to 
proliferate, migrate, grow in an anchorage independent manner, and undergo 
apoptosis upon genotoxic stimulation. Coherent with these observations, our 
experiment of in vivo xenotransplantation show that enhanced expression of mir-143 
and mir-145 provokes a sensible delay in the growth of subcutaneous tumors. We 
have also found that re-establishment of mir-143 and mir-145 oncosuppressor 
functions in tumoral cell lines, can impose a proliferation block/delay that, upon 
prolonged culturing, might eventually result in a counter-selection effect, in our case 
loss of transgene expression. Hence, we speculate that for long term (more than two 
weeks) studies of microRNAs with oncosuppressor function, a reversible and 
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controllable expression system might be more appropriate than a constitutive one 
although, in the real manifestations of tumoral pathology, loss of oncosuppressor 
expression is supposed to be permanent.  
The definition of the subset of microRNA target genes that mediate an 
oncosuppressor or oncogenic effect is one of the most intriguing aspects of this field 
of study, as it is probably the element that by itself can explain most of the 
mechanism of action which eventually need to be tackled by a therapeutical 
instrument. Reports abound where a single microRNA-target gene interaction is 
claimed to be responsible for a given effect, although search engines typically return 
hundreds of target transcripts to a single microRNA query. In our study of the mir-
143 and -145 regulatory action, we tried to focus on a larger number of targets 
chosen for being cotargeted by the two transcripts and for belonging to the IGF/EGF 
signal transduction pathway. We found that, in addition to k-RAS, a previously 
known mir-143 target (Chen et al., 2009), the two microRNAs downregulate two 
important mediators downstream of k-RAS. Both microRNAs do indeed target the 
KLF5 transcription factor, which synergizes with k-RAS in colorectal transformation 
(Nandan  et al., 2008), and mir-143 targets BRAF, the immediate downstream 
mediator of KRAS activation. Notably, we have found a target site for mir-143 in the 
coding sequence (CDS) of the BRAF mRNA. Search engines normally neglect this 
region, as well as the 5‘ UTR, and we believe this is detrimental to the 
comprehension of microRNA biology, considering that other articles have reported 
the occurrence of microRNA target sites in regions other than the 3‘UTR (Tay et al., 
2008). In addition to that, we found that both microRNAs target CD44, a receptor 
that transduces survival signals to the cell. To establish whether the decrease in any 
of these target proteins was dispensable for mir-143 and mir-145 action, we 
expressed exogenous target genes along with the microRNAs. Given the intrinsic 
complexity of such an approach, we have investigated the single contribution of the 
downregulation in target protein levels on the overall oncosuppression phenomena 
we observed. We have thus found that any decrease in single target proteins is 
involved to a different extent in the phenotype of growth suppression and, based also 
on published evidence, we conclude that the microRNAs mir-143 and -145 act in a 
concerted manner to suppress the IGF-EGF receptor pathway at multiple levels. It 
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has been shown that the regulatory network of a microRNA comprises a small 
number of genes that are heavily affected at the protein level, and a larger group of 
genes that are mildly downregulated (Baek et al., 2008;  Selbach et al., 2008), where 
secondary effects are to be counted as well. Although we believe that other mir-143 
and mir-145 targets could be implicated in cell growth and survival, we propose that 
the concerted action on the EGF-IGF signaling pathway and on the CD44 survival 
pathway can account for a substantial part of the oncosuppression properties of this 
regulatory system. Microarray profiling experiments are underway to observe whole 
transcriptome changes in CRC cells that are forced to re-express mir-143 and -145 
and further define the affected pathways.  
MicroRNAs have emerged as key players in posttranscriptional gene regulation, and 
as indispensable mediators of several important biological processes, including 
tumorigenesis and tissue homeostasis and regeneration (Esquela-Kerscher et al., 
2006). In their unique chemistry lies a great advantage over protein-encoding genes: 
it is becoming evident that, if a gene therapy would be required, their synthesis, 
stability, and delivery to target cells is much more feasible and immediate than for 
proteins. Very recently, it has been shown that the use of an adeno-associated virus 
for restoration of a microRNA in a murine model of hepatocellular carcinoma has a 
tremendous impact on tumor progression (Kota et al., 2009). Besides viral-based 
therapy, other studies support the possibility that microRNAs can be delivered 
systemically to target organs, without the risk of immune reaction (Yun et al., 2003). 
This prompts for extensive investigation of the potential role of microRNAs in 
disease and as instruments of molecular medicine.  
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